

AN

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number
WO 01/94385 A2

(51) International Patent Classification⁷: **C07K 14/00**

(21) International Application Number: **PCT/EP01/06380**

(22) International Filing Date: **5 June 2001 (05.06.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/208,912 **5 June 2000 (05.06.2000)** **US**

(71) Applicant (for all designated States except US): **BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).**

(72) Inventor; and

(75) Inventor/Applicant (for US only): **RAMAKRISHNAN, Shyam [IN/US]; 76 Euston Road Apt. #10, Brighton, MA 02135 (US).**

(74) Common Representative: **BAYER AKTIENGESELLSCHAFT; 51368 Leverkusen (DE).**


(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**

(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/94385 A2

(54) Title: **REGULATION OF HUMAN HM74-LIKE G PROTEIN COUPLED RECEPTOR**

(57) Abstract: Reagents which regulate human HM74-like G protein coupled receptor can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, CNS diseases such as Parkinson's disease, cardiovascular diseases such as acute heart failure, hypotension, hypertension, angina pectoris, and myocardial infarction, urinary retention, osteoporosis, obesity, ulcers, asthma, inflammation, allergies, multiple sclerosis, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, several mental retardation, and dyskinesias, such as Huntington's disease and Tourett's syndrome.

REGULATION OF HUMAN HM74-LIKE G PROTEIN COUPLED RECEPTOR

TECHNICAL FIELD OF THE INVENTION

- 5 The invention relates to the area of G-protein coupled receptors. More particularly, it relates to the area of HM74-like G protein coupled receptors and their regulation.

BACKGROUND OF THE INVENTION

10 *G-Protein Coupled Receptors*

- Many medically significant biological processes are mediated by signal transduction pathways that involve G-proteins (Lefkowitz, *Nature* 351, 353-354, 1991). The family of G-protein coupled receptors (GPCR) includes receptors for hormones, neurotransmitters, growth factors, and viruses. Specific examples of GPCRs include
15 receptors for such diverse agents as dopamine, calcitonin, adrenergic hormones, endothelin, cAMP, adenosine, acetylcholine, serotonin, histamine, thrombin, kinin, follicle stimulating hormone, opsins, endothelial differentiation gene-1, rhodopsins, odorants, cytomegalovirus, G-proteins themselves, effector proteins such as
20 phospholipase C, adenylyl cyclase, and phosphodiesterase, and actuator proteins such as protein kinase A and protein kinase C.

- GPCRs possess seven conserved membrane-spanning domains connecting at least eight divergent hydrophilic loops. GPCRs (also known as 7TM receptors) have been
25 characterized as including these seven conserved hydrophobic stretches of about 20 to 30 amino acids, connecting at least eight divergent hydrophilic loops. Most GPCRs have single conserved cysteine residues in each of the first two extracellular loops, which form disulfide bonds that are believed to stabilize functional protein structure. The seven transmembrane regions are designated as TM1, TM2, TM3,
30 TM4, TM5, TM6, and TM7. TM3 has been implicated in signal transduction.

Phosphorylation and lipidation (palmitylation or farnesylation) of cysteine residues can influence signal transduction of some GPCRs. Most GPCRs contain potential phosphorylation sites within the third cytoplasmic loop and/or the carboxy terminus. For several GPCRs, such as the β -adrenergic receptor, phosphorylation by protein
5 kinase A and/or specific receptor kinases mediates receptor desensitization.

For some receptors, the ligand binding sites of GPCRs are believed to comprise hydrophilic sockets formed by several GPCR transmembrane domains. The hydrophilic sockets are surrounded by hydrophobic residues of the GPCRs. The
10 hydrophilic side of each GPCR transmembrane helix is postulated to face inward and form a polar ligand binding site. TM3 has been implicated in several GPCRs as having a ligand binding site, such as the TM3 aspartate residue. TM5 serines, a TM6 asparagine, and TM6 or TM7 phenylalanines or tyrosines also are implicated in ligand binding.

15 GPCRs are coupled inside the cell by heterotrimeric G-proteins to various intracellular enzymes, ion channels, and transporters (*see Johnson et al., Endoc. Rev. 10, 317-331, 1989*). Different G-protein alpha-subunits preferentially stimulate particular effectors to modulate various biological functions in a cell. Phos-
20 phosphorylation of cytoplasmic residues of GPCRs is an important mechanism for the regulation of some GPCRs. For example, in one form of signal transduction, the effect of hormone binding is the activation inside the cell of the enzyme, adenylate cyclase. Enzyme activation by hormones is dependent on the presence of the nucleotide GTP. GTP also influences hormone binding. A G-protein connects the
25 hormone receptor to adenylate cyclase. G-protein exchanges GTP for bound GDP when activated by a hormone receptor. The GTP-carrying form then binds to activated adenylate cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-protein itself, returns the G-protein to its basal, inactive form. Thus, the G-protein serves a dual role, as an intermediate that relays the signal from receptor to effector, and as a
30 clock that controls the duration of the signal.

Over the past 15 years, nearly 350 therapeutic agents targeting GPCRs receptors have been successfully introduced onto the market. This indicates that these receptors have an established, proven history as therapeutic targets. Clearly, there is an on-going need for identification and characterization of further GPCRs which can play a
5 role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, CNS diseases such as Parkinson's disease, cardiovascular diseases such as acute heart failure, hypotension, hypertension, angina pectoris, and myocardial infarction,
10 urinary retention, osteoporosis, ulcers, asthma, inflammation, allergies, multiple sclerosis, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, several mental retardation, and dyskinesias, such as Huntington's disease and Tourett's syndrome.

15 Because of the wide-spread distribution of GPCRs with diverse biological effects, there is a need in the art to identify additional members of the GPCR family whose activity can be regulated to provide therapeutic effects.

20 SUMMARY OF THE INVENTION

It is an object of the invention to provide reagents and methods of regulating a human HM74-like G protein coupled receptor (HM74-like GPCR). This and other
25 objects of the invention are provided by one or more of the embodiments described below.

One embodiment of the invention is a HM74-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:

30 amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 2;

- 4 -

the amino acid sequence shown in SEQ ID NO. 2;

5 amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 5;

the amino acid sequence shown in SEQ ID NO. 5;

10 amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 6;

the amino acid sequence shown in SEQ ID NO. 6;

15 amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 7; and

the amino acid sequence shown in SEQ ID NO. 7.

20 Yet another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a HM74-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:

25 amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 2;

the amino acid sequence shown in SEQ ID NO. 2;

30 amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 5;

the amino acid sequence shown in SEQ ID NO. 5;

amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 6;

5

the amino acid sequence shown in SEQ ID NO. 6;

amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 7; and

10

the amino acid sequence shown in SEQ ID NO. 7.

Binding between the test compound and the HM74-like GPCR polypeptide is detected. A test compound which binds to the HM74-like GPCR polypeptide is thereby identified as a potential agent for decreasing extracellular matrix degradation. The agent can work by decreasing the activity of the HM74-like GPCR.

15

Another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a polynucleotide encoding a HM74-like GPCR polypeptide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:

20

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 1;

25

the nucleotide sequence shown in SEQ ID NO. 1;

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 3; and

30

the nucleotide sequence shown in SEQ ID NO. 3.

Binding of the test compound to the polynucleotide is detected. A test compound which binds to the polynucleotide is identified as a potential agent for decreasing extracellular matrix degradation. The agent can work by decreasing the amount of the
5 HM74-like GPCR through interacting with the HM74-like GPCR mRNA.

Another embodiment of the invention is a method of screening for agents which regulate extracellular matrix degradation. A test compound is contacted with a HM74-like GPCR polypeptide comprising an amino acid sequence selected from the
10 group consisting of:

amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 2;

15 the amino acid sequence shown in SEQ ID NO. 2;

amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 5;

20 the amino acid sequence shown in SEQ ID NO. 5;

amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 6;

25 the amino acid sequence shown in SEQ ID NO. 6;

amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 7; and

30 the amino acid sequence shown in SEQ ID NO. 7.

A HM74-like GPCR activity of the polypeptide is detected. A test compound which increases HM74-like GPCR activity of the polypeptide relative to HM74-like GPCR activity in the absence of the test compound is thereby identified as a potential agent for increasing extracellular matrix degradation. A test compound which decreases
5 HM74-like GPCR activity of the polypeptide relative to HM74-like GPCR activity in the absence of the test compound is thereby identified as a potential agent for decreasing extracellular matrix degradation.

Even another embodiment of the invention is a method of screening for agents which
10 decrease extracellular matrix degradation. A test compound is contacted with a HM74-like GPCR product of a polynucleotide which comprises a nucleotide sequence selected from the group consisting of:

nucleotide sequences which are at least about 50% identical to the nucleotide
15 sequence shown in SEQ ID NO. 1;

the nucleotide sequence shown in SEQ ID NO. 1;

nucleotide sequences which are at least about 50% identical to the nucleotide
20 sequence shown in SEQ ID NO. 3; and

the nucleotide sequence shown in SEQ ID NO. 3.

Binding of the test compound to the HM74-like GPCR product is detected. A test
25 compound which binds to the HM74-like GPCR product is thereby identified as a potential agent for decreasing extracellular matrix degradation.

Still another embodiment of the invention is a method of reducing extracellular matrix degradation. A cell is contacted with a reagent which specifically binds to a
30 polynucleotide encoding a HM74-like GPCR polypeptide or the product encoded by

the polynucleotide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:

5 nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 1;

the nucleotide sequence shown in SEQ ID NO. 1;

10 nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 3; and

the nucleotide sequence shown in SEQ ID NO. 3.

15 HM74-like GPCR activity in the cell is thereby decreased.

The invention thus provides an HM74-like G protein coupled receptor which can be used to identify test compounds which may act as agonists or antagonists at the receptor site and which can be regulated to provide therapeutic effects.

20 BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the DNA-sequence encoding a HM74-like GPCR polypeptide.

Fig. 2 shows the amino acid sequence deduced from the DNA-sequence of Fig.1.

Fig. 3 shows the DNA-sequence encoding a HM74-like GPCR polypeptide.

25 Fig. 4 shows the amino acid sequence of a human protein identified with SwissProt Accession No. P49019.

Fig. 5 shows the amino acid sequence of a HM74-like GPCR polypeptide.

Fig. 6 shows the amino acid sequence of a HM74-like GPCR polypeptide.

Fig. 7 shows the amino acid sequence of a HM74-like GPCR polypeptide.

30 Fig. 8 shows the alignment of HM74-like GPCR polypeptide of Fig. 2 and the HM74 protein having SwissProt Accession No. P49019 of Fig. 4.

Fig. 9 shows the results of a BLOCK search.

Fig. 10 shows the amino acid sequence of a HM74-like GPCR polypeptide.

Transmembrane helix is indicated.

5 DETAILED DESCRIPTION OF THE INVENTION

The invention relates to an isolated polynucleotide encoding a HM74-like GPCR polypeptide and being selected from the group consisting of:

- 10 a) a polynucleotide encoding a HM74-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:

amino acid sequences which are at least about 50% identical to
the amino acid sequence shown in SEQ ID NO. 2;

- 15 the amino acid sequence shown in SEQ ID NO. 2;

amino acid sequences which are at least about 50% identical to
the amino acid sequence shown in SEQ ID NO. 5;

the amino acid sequence shown in SEQ ID NO. 5;

- 20 amino acid sequences which are at least about 50% identical to
the amino acid sequence shown in SEQ ID NO. 6;

the amino acid sequence shown in SEQ ID NO. 6;

amino acid sequences which are at least about 50% identical to
the amino acid sequence shown in SEQ ID NO. 7; and

the amino acid sequence shown in SEQ ID NO. 7.

25

- b) a polynucleotide comprising the sequence of SEQ ID NOS: 1 or 3;

- c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b);

30

- d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code; and
- 5 e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d).

Furthermore, it has been discovered by the present applicant that a novel HM74-like GPCR, particularly a human HM74-like GPCR, is a discovery of the present
10 invention. Human HM74-like GPCR is 42% identical over 286 amino acids to the human protein identified with SwissProt Accession No. P49019 (SEQ ID NO. 4) and annotated as a "probable G protein-coupled rece HM74." Human HM74-like GPCR contains transmembrane helices from amino acids 95 to 114, 131 to 149, 169 to 187, 211 to 228, 256 to 273, 298 to 316, and 339 to 356. A search of the Prosite database
15 indicates that human HM74-like GPCR is a G protein-coupled receptor (PS00237 178->195, G protein receptor, PDOC00210). BLOCK search results are shown in FIG. 2. Human HM74-like GPCR is expected to bind a ligand to produce a biological effect or activity typical of GPCRs, such as cyclic AMP formation, mobilization of intracellular and calcium, or phosphoinositide metabolism.

20

It is also a discovery of the present invention that human HM74-like GPCR can be used in therapeutic methods to treat disorders such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, cardiovascular diseases such as acute heart failure,
25 hypotension, hypertension, angina pectoris, and myocardial infarction, urinary retention, osteoporosis, inflammation, ulcers, asthma, allergies, multiple sclerosis, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, several mental retardation, and dyskinesias, such as Parkinson's disease, Huntington's disease, and
30 Tourett's syndrome. Human HM74-like GPCR also can be used to screen for human HM74-like GPCR agonists and antagonists.

Polypeptides

HM74-like GPCR polypeptides according to the invention comprise at least 15, 20,
5 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400 contiguous amino acids
selected from the amino acid sequence shown in SEQ ID NO. 2 or a biologically
active variant thereof, as defined below. An HM74-like GPCR polypeptide of the
invention therefore can be a portion of an HM74-like GPCR, a full-length HM74-like
GPCR, or a fusion protein comprising all or a portion of an HM74-like GPCR.

Biologically Active Variants

HM74-like GPCR polypeptide variants which are biologically active, *i.e.*, retain the
ability to bind a ligand to produce a biological effect, such as cyclic AMP formation,
15 mobilization of intracellular calcium, or phosphoinositide metabolism, also are
HM74-like GPCR polypeptides. Preferably, naturally or non-naturally occurring
HM74-like GPCR polypeptide variants have amino acid sequences which are at least
about 50, preferably about 75, 90, 96, or 98% identical to an amino acid sequence
shown in SEQ ID NO. 2 or a fragment thereof. Percent identity between a putative
20 HM74-like GPCR polypeptide variant and an amino acid sequence of SEQ ID NO. 2
is determined using the Blast2 alignment program (Blosun62, Expect 10, standard
genetic codes).

Variations in percent identity can be due, for example, to amino acid substitutions,
25 insertions, or deletions. Amino acid substitutions are defined as one for one amino
acid replacements. They are conservative in nature when the substituted amino acid
has similar structural and/or chemical properties. Examples of conservative
replacements are substitution of a leucine with an isoleucine or valine, an aspartate
with a glutamate, or a threonine with a serine.

Amino acid insertions or deletions are changes to or within an amino acid sequence. They typically fall in the range of about 1 to 5 amino acids. Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity of an HM74-like GPCR polypeptide can be found using computer programs well known in the art, such as DNASTAR software. Whether an amino acid change results in a biologically active HM74-like GPCR polypeptide can readily be determined by assaying for binding to a ligand or by conducting a functional assay, such as those described in the specific examples, below.

Fusion Proteins

Fusion proteins are useful for generating antibodies against HM74-like GPCR polypeptide amino acid sequences and for use in various assay systems. For example, fusion proteins can be used to identify proteins which interact with portions of an HM74-like GPCR polypeptide. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.

An HM74-like GPCR polypeptide fusion protein comprises two polypeptide segments fused together by means of a peptide bond. The first polypeptide segment comprises at least 15, 20, 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400 or more contiguous amino acids of SEQ ID NO. 2 or a biologically active variant thereof. The first polypeptide segment also can comprise full-length HM74-like GPCR.

The second polypeptide segment can be a full-length protein or a protein fragment. Proteins commonly used in fusion protein construction include β -galactosidase, β -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horse-

radish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT). Additionally, epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. A fusion protein also can be engineered to contain a cleavage site located between the HM74-like GPCR polypeptide-encoding sequence and the heterologous protein sequence, so that the HM74-like GPCR polypeptide can be cleaved and purified away from the heterologous moiety.

A fusion protein can be synthesized chemically, as is known in the art. Preferably, a fusion protein is produced by covalently linking two polypeptide segments or by standard procedures in the art of molecular biology. Recombinant DNA methods can be used to prepare fusion proteins, for example, by making a DNA construct which comprises coding sequences selected from SEQ ID NO. 1 or 3 in proper reading frame with nucleotides encoding the second polypeptide segment and expressing the DNA construct in a host cell, as is known in the art. Many kits for constructing fusion proteins are available from companies such as Promega Corporation (Madison, WI), Stratagene (La Jolla, CA), CLONTECH (Mountain View, CA), Santa Cruz Biotechnology (Santa Cruz, CA), MBL International Corporation (MIC; Watertown, MA), and Quantum Biotechnologies (Montreal, Canada; 1-888-DNA-KITS).

Identification of Species Homologs

Species homologs of human HM74-like GPCR polypeptide can be obtained using HM74-like GPCR polynucleotides (described below) to make suitable probes or primers for screening cDNA expression libraries from other species, such as mice, monkeys, or yeast, identifying cDNAs which encode homologs of HM74-like GPCR polypeptide, and expressing the cDNAs as is known in the art.

Polynucleotides

5 An HM74-like GPCR polynucleotide can be single- or double-stranded and comprises a coding sequence or the complement of a coding sequence for an HM74-like GPCR polypeptide. A nucleotide sequence encoding the HM74-like GPCR having SEQ ID NO. 2 is shown in SEQ ID NO. 1.

10 Degenerate nucleotide sequences encoding human HM74-like GPCR polypeptides, as well as homologous nucleotide sequences which are at least about 50, preferably about 75, 90, 96, or 98% identical to the nucleotide sequence shown in SEQ ID NO. 1 or its complement also are HM74-like GPCR polynucleotides. Percent sequence identity between the sequences of two polynucleotides is determined using computer programs such as ALIGN which employ the FASTA algorithm, using an affine gap search with a gap open penalty of -12 and a gap extension penalty of -2.
15 Complementary DNA (cDNA) molecules, species homologs, and variants of HM74-like GPCR polynucleotides which encode biologically active HM74-like GPCR polypeptides also are HM74-like GPCR polynucleotides.

20 Identification of Polynucleotide Variants and Homologs

Variants and homologs of the HM74-like GPCR polynucleotides described above also are HM74-like GPCR polynucleotides. Typically, homologous HM74-like GPCR polynucleotide sequences can be identified by hybridization of candidate
25 polynucleotides to known HM74-like GPCR polynucleotides under stringent conditions, as is known in the art. For example, using the following wash conditions--2X SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0), 0.1% SDS, room temperature twice, 30 minutes each; then 2X SSC, 0.1% SDS, 50°C once, 30 minutes; then 2X SSC, room temperature twice, 10 minutes each--homologous sequences can be
30 identified which contain at most about 25-30% basepair mismatches. More

preferably, homologous nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.

Species homologs of the HM74-like GPCR polynucleotides disclosed herein also can
5 be identified by making suitable probes or primers and screening cDNA expression
libraries from other species, such as mice, monkeys, or yeast. Human variants of
HM74-like GPCR polynucleotides can be identified, for example, by screening
human cDNA expression libraries. It is well known that the T_m of a double-stranded
DNA decreases by 1-1.5°C with every 1% decrease in homology (Bonner *et al.*, *J.*
10 *Mol. Biol.* 81, 123 (1973). Variants of human HM74-like GPCR polynucleotides or
HM74-like GPCR polynucleotides of other species can therefore be identified by
hybridizing a putative homologous HM74-like GPCR polynucleotide with a poly-
nucleotide having a nucleotide sequence of SEQ ID NO. 1 or 3 or the complement
thereof to form a test hybrid. The melting temperature of the test hybrid is compared
15 with the melting temperature of a hybrid comprising polynucleotides having
perfectly complementary nucleotide sequences, and the number or percent of
basepair mismatches within the test hybrid is calculated.

Nucleotide sequences which hybridize to HM74-like GPCR polynucleotides or their
20 complements following stringent hybridization and/or wash conditions also are
HM74-like GPCR polynucleotides. Stringent wash conditions are well known and
understood in the art and are disclosed, for example, in Sambrook *et al.*, MOLECULAR
CLONING: A LABORATORY MANUAL, 2d ed., 1989, at pages 9.50-9.51.

Typically, for stringent hybridization conditions a combination of temperature and
25 salt concentration should be chosen that is approximately 12-20°C below the
calculated T_m of the hybrid under study. The T_m of a hybrid between an HM74-like
GPCR polynucleotide having a nucleotide sequence shown in SEQ ID NO. 1 or the
complement thereof and a polynucleotide sequence which is at least about 50,
30 preferably about 75, 90, 96, or 98% identical to one of those nucleotide sequences

can be calculated, for example, using the equation of Bolton and McCarthy, *Proc. Natl. Acad. Sci. U.S.A.* 48, 1390 (1962):

$$T_m = 81.5^{\circ}\text{C} - 16.6(\log_{10}[\text{Na}^+]) + 0.41(\%G + C) - 0.63(\%\text{formamide}) - 600/l,$$

5 where l = the length of the hybrid in basepairs.

Stringent wash conditions include, for example, 4X SSC at 65°C, or 50% formamide, 4X SSC at 42°C, or 0.5X SSC, 0.1% SDS at 65°C. Highly stringent wash conditions include, for example, 0.2X SSC at 65°C.

10

Preparation of Polynucleotides

An HM74-like GPCR polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids. Polynucleotides can be made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated HM74-like GPCR polynucleotides. For example, restriction enzymes and probes can be used to isolate polynucleotide fragments which comprises HM74-like GPCR nucleotide sequences. Isolated polynucleotides are in preparations which are free or at least 70, 80, or 90% free of other molecules.

25 HM74-like GPCR cDNA molecules can be made with standard molecular biology techniques, using HM74-like GPCR mRNA as a template. HM74-like GPCR cDNA molecules can thereafter be replicated using molecular biology techniques known in the art and disclosed in manuals such as Sambrook *et al.* (1989). An amplification technique, such as PCR, can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or cDNA as a template.

30

Alternatively, synthetic chemistry techniques can be used to synthesize HM74-like GPCR polynucleotides. The degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which will encode an HM74-like GPCR polypeptide having, for example, an amino acid sequence shown in SEQ ID NO. 2 or
5 a biologically active variant thereof.

Extending Polynucleotides

Various PCR-based methods can be used to extend the nucleic acid sequences
10 encoding human HM74-like GPCR to detect upstream sequences such as promoters and regulatory elements. For example, restriction-site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, *PCR Methods Applic.* 2, 318-322, 1993). Genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences
15 are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

20 Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a known region (Triglia *et al.*, *Nucleic Acids Res.* 16, 8186, 1988). Primers can be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, Minn.), to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the
25 target sequence at temperatures about 68-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which can be used is capture PCR, which involves PCR amplifi-
30 cation of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom *et al.*, *PCR Methods Applic.* 1, 111-119, 1991). In

this method, multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

5 Another method which can be used to retrieve unknown sequences is that of Parker *et al.*, *Nucleic Acids Res.* 19, 3055-3060, 1991). Additionally, PCR, nested primers, and PROMOTERFINDER libraries (CLONTECH, Palo Alto, Calif.) can be used to walk genomic DNA (CLONTECH, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

10

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Randomly-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo
15 d(T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' non-transcribed regulatory regions.

20

Commercially available capillary electrophoresis systems can be used to analyze the size or confirm the nucleotide sequence of PCR or sequencing products. For example, capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity can be converted to electrical signal using appropriate software (e.g. GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the
25 entire process from loading of samples to computer analysis and electronic data display can be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

Obtaining Polypeptides

HM74-like GPCR polypeptides can be obtained, for example, by purification from human cells, by expression of HM74-like GPCR polynucleotides, or by direct
5 chemical synthesis.

Protein Purification

HM74-like GPCR polypeptides can be purified from any cell which expresses the
10 receptor, including host cells which have been transfected with HM74-like GPCR polynucleotides which express such polypeptides. Colon, adenocarcinoma, liver, and kidney are particularly useful sources of HM74-like polypeptides. A purified HM74-like GPCR polypeptide is separated from other compounds which normally associate with the HM74-like GPCR polypeptide in the cell, such as certain proteins, carbohy-
15 drates, or lipids, using methods well-known in the art. Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis.

20 An HM74-like GPCR polypeptide can be conveniently isolated as a complex with its associated G protein, as described in the specific examples, below. A preparation of purified HM74-like GPCR polypeptides is at least 80% pure; preferably, the preparations are 90%, 95%, or 99% pure. Purity of the preparations can be assessed by any means known in the art, such as SDS-polyacrylamide gel electrophoresis.

25

Expression of Polynucleotides

To express an HM74-like GPCR polypeptide, an HM74-like GPCR polynucleotide can be inserted into an expression vector which contains the necessary elements for
30 the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art can be used to construct expression vectors

- 20 -

containing sequences encoding HM74-like GPCR polypeptides and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described, for example, in Sambrook *et al.* (1989) and in Ausubel *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1989.

A variety of expression vector/host systems can be utilized to contain and express sequences encoding an HM74-like GPCR polypeptide. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect cell systems infected with virus expression vectors (*e.g.*, baculovirus), plant cell systems transformed with virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmids), or animal cell systems.

The control elements or regulatory sequences are those non-translated regions of the vector -- enhancers, promoters, 5' and 3' untranslated regions -- which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORT1 plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin promoter can be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (*e.g.*, heat shock, RUBISCO, and storage protein genes) or from plant viruses (*e.g.*, viral promoters or leader sequences) can be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a

nucleotide sequence encoding an HM74-like GPCR polypeptide, vectors based on SV40 or EBV can be used with an appropriate selectable marker.

Bacterial and Yeast Expression Systems

5

In bacterial systems, a number of expression vectors can be selected depending upon the use intended for the HM74-like GPCR polypeptide. For example, when a large quantity of an HM74-like GPCR polypeptide is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multi-
10 functional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene). In a BLUESCRIPT vector, a sequence encoding the HM74-like GPCR polypeptide can be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid
15 protein is produced. pIN vectors (Van Heeke & Schuster, *J. Biol. Chem.* 264, 5503-5509, 1989) or pGEX vectors (Promega, Madison, Wis.) also can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of
20 free glutathione. Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast *Saccharomyces cerevisiae*, a number of vectors containing constitutive
25 or inducible promoters such as alpha factor, alcohol oxidase, and PGH can be used. For reviews, see Ausubel *et al.* (1989) and Grant *et al.*, *Methods Enzymol.* 153, 516-544, 1987.

Plant and Insect Expression Systems

If plant expression vectors are used, the expression of sequences encoding HM74-like GPCR polypeptides can be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV (Takamatsu, *EMBO J.* 6, 307-311, 1987). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used (Coruzzi *et al.*, *EMBO J.* 3, 1671-1680, 1984; Broglie *et al.*, *Science* 224, 838-843, 1984; Winter *et al.*, *Results Probl. Cell Differ.* 17, 85-105, 1991). These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (e.g., Hobbs or Murray, in MCGRAW HILL YEARBOOK OF SCIENCE AND TECHNOLOGY, McGraw Hill, New York, N.Y., pp. 191-196, 1992).

An insect system also can be used to express an HM74-like GPCR polypeptide. For example, in one such system *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. Sequences encoding HM74-like GPCR polypeptides can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of HM74-like GPCR polypeptides will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which HM74-like GPCR polypeptides can be expressed (Engelhard *et al.*, *Proc. Nat. Acad. Sci.* 91, 3224-3227, 1994).

Mammalian Expression Systems

A number of viral-based expression systems can be used to express HM74-like GPCR polypeptides in mammalian host cells. For example, if an adenovirus is used

- as an expression vector, sequences encoding HM74-like GPCR polypeptides can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome can be used to obtain a viable virus which is capable of
- 5 expressing an HM74-like GPCR polypeptide in infected host cells (Logan & Shenk, *Proc. Natl. Acad. Sci.* 81, 3655-3659, 1984). If desired, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.
- 10 Human artificial chromosomes (HACs) also can be used to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6M to 10M are constructed and delivered to cells via conventional delivery methods (*e.g.*, liposomes, polycationic amino polymers, or vesicles).
- 15 Specific initiation signals also can be used to achieve more efficient translation of sequences encoding HM74-like GPCR polypeptides. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding an HM74-like GPCR polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or
- 20 translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins,
- 25 both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used (see Scharf *et al.*, *Results Probl. Cell Differ.* 20, 125-162, 1994).

Host Cells

A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed HM74-like GPCR polypeptide in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.

Stable expression is preferred for long-term, high-yield production of recombinant proteins. For example, cell lines which stably express HM74-like GPCR polypeptides can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a selective medium. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced HM74-like GPCR sequences. Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. See, for example, ANIMAL CELL CULTURE, R.I. Freshney, ed., 1986.

Any number of selection systems can be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler *et al.*, *Cell* 11, 223-32, 1977) and adenine phosphoribosyltransferase (Lowy *et al.*, *Cell* 22, 817-23, 1980) genes which can be employed in *tk* or *aprt* cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as

the basis for selection. For example, *dhfr* confers resistance to methotrexate (Wigler *et al.*, *Proc. Natl. Acad. Sci.* 77, 3567-70, 1980), *npt* confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin *et al.*, *J. Mol. Biol.* 150, 1-14, 1981), and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin
5 acetyltransferase, respectively (Murray, 1992, *supra*). Additional selectable genes have been described. For example, *trpB* allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, *Proc. Natl. Acad. Sci.* 85, 8047-51, 1988). Visible markers
10 such as anthocyanins, β -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes *et al.*, *Methods Mol. Biol.* 55, 121-131, 1995).

Detecting Expression of Polypeptides

15

Although the presence of marker gene expression suggests that the HM74-like GPCR polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding an HM74-like GPCR polypeptide is inserted within a marker gene sequence, transformed cells containing sequences which
20 encode an HM74-like GPCR polypeptide can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding an HM74-like GPCR polypeptide under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the HM74-like GPCR polynucleotide.

25

Alternatively, host cells which contain an HM74-like GPCR polynucleotide and which express an HM74-like GPCR polypeptide can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or
30 immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein. For

example, the presence of a polynucleotide sequence encoding an HM74-like GPCR polypeptide can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding an HM74-like GPCR polypeptide. Nucleic acid amplification-based assays involve the
5 use of oligonucleotides selected from sequences encoding an HM74-like GPCR polypeptide to detect transformants which contain an HM74-like GPCR polynucleotide.

A variety of protocols for detecting and measuring the expression of an HM74-like GPCR polypeptide, using either polyclonal or monoclonal antibodies specific for the
10 polypeptide, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on an HM74-like GPCR polypeptide can be used, or a competitive binding assay can be employed. These and other assays are
15 described in Hampton *et al.*, SEROLOGICAL METHODS: A LABORATORY MANUAL, APS Press, St. Paul, Minn., 1990) and Maddox *et al.*, *J. Exp. Med.* 158, 1211-1216, 1983).

A wide variety of labels and conjugation techniques are known by those skilled in the
20 art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding HM74-like GPCR polypeptides include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, sequences encoding an HM74-like GPCR polypeptide can be cloned
25 into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes *in vitro* by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical).
30 Suitable reporter molecules or labels which can be used for ease of detection include

radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Expression and Purification of Polypeptides

5

Host cells transformed with nucleotide sequences encoding an HM74-like GPCR polypeptide can be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The polypeptide produced by a transformed cell can be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode HM74-like GPCR polypeptides can be designed to contain signal sequences which direct secretion of soluble HM74-like GPCR polypeptides through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound HM74-like GPCR polypeptide.

15

As discussed above, other constructions can be used to join a sequence encoding an HM74-like GPCR polypeptide to a nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). Inclusion of cleavable linker sequences such as those specific for Factor Xa or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the HM74-like GPCR polypeptide also can be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing an HM74-like GPCR polypeptide and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilized metal ion affinity chromatography, as described in Porath *et al.*, *Prot. Exp. Purif.* 3, 263-281, 1992), while the enterokinase cleavage site provides a means for purifying the HM74-like GPCR polypeptide from the

30

fusion protein. Vectors which contain fusion proteins are disclosed in Kroll *et al.*, *DNA Cell Biol.* 12, 441-453, 1993.

Chemical Synthesis

5

Sequences encoding an HM74-like GPCR polypeptide can be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers *et al.*, *Nucl. Acids Res. Symp. Ser.* 215-223, 1980; Horn *et al.* *Nucl. Acids Res. Symp. Ser.* 225-232, 1980). Alternatively, an HM74-like GPCR polypeptide itself can be produced
10 using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques (Merrifield, *J. Am. Chem. Soc.* 85, 2149-2154, 1963; Roberge *et al.*, *Science* 269, 202-204, 1995). Protein synthesis can be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer
15 (Perkin Elmer). Optionally, fragments of HM74-like GPCR polypeptides can be separately synthesized and combined using chemical methods to produce a full-length molecule.

The newly synthesized peptide can be substantially purified by preparative high
20 performance liquid chromatography (*e.g.*, Creighton, *PROTEINS: STRUCTURES AND MOLECULAR PRINCIPLES*, WH Freeman and Co., New York, N.Y., 1983). The composition of a synthetic HM74-like GPCR polypeptide can be confirmed by amino acid analysis or sequencing (*e.g.*, the Edman degradation procedure; *see* Creighton, *supra*). Additionally, any portion of the amino acid sequence of the
25 HM74-like GPCR polypeptide can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.

Production of Altered Polypeptides

As will be understood by those of skill in the art, it may be advantageous to produce HM74-like GPCR polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences disclosed herein can be engineered using methods generally known in the art to alter HM74-like GPCR polypeptide-encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences. For example, site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

Antibodies

Any type of antibody known in the art can be generated to bind specifically to an epitope of an HM74-like GPCR polypeptide. "Antibody" as used herein includes intact immunoglobulin molecules, as well as fragments thereof, such as Fab, F(ab')₂, and Fv, which are capable of binding an epitope of an HM74-like GPCR polypeptide. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous amino acids may require more, e.g., at least 15, 25, or 50 amino acids.

An antibody which specifically binds to an epitope of an HM74-like GPCR polypeptide can be used therapeutically, as well as in immunochemical assays, such as Western blots, ELISAs, radioimmunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art. Various immunoassays can be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays are well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody which specifically binds to the immunogen.

10

Typically, an antibody which specifically binds to an HM74-like GPCR polypeptide provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay. Preferably, antibodies which specifically bind to HM74-like GPCR polypeptides do not detect other proteins in immunochemical assays and can immunoprecipitate an HM74-like GPCR polypeptide from solution.

15

HM74-like GPCR polypeptides can be used to immunize a mammal, such as a mouse, rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies. If desired, an HM74-like GPCR polypeptide can be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin. Depending on the host species, various adjuvants can be used to increase the immunological response. Such adjuvants include, but are not limited to, Freund's adjuvant, mineral gels (e.g., aluminum hydroxide), and surface active substances (e.g. lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol). Among adjuvants used in humans, BCG (*bacilli Calmette-Guerin*) and *Corynebacterium parvum* are especially useful.

20

25

Monoclonal antibodies which specifically bind to an HM74-like GPCR polypeptide can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These techniques include, but are not

30

limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler *et al.*, *Nature* 256, 495-497, 1985; Kozbor *et al.*, *J. Immunol. Methods* 81, 31-42, 1985; Cote *et al.*, *Proc. Natl. Acad. Sci.* 80, 2026-2030, 1983; Cole *et al.*, *Mol. Cell Biol.* 62, 109-120, 1984).

5

In addition, techniques developed for the production of "chimeric antibodies," the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used (Morrison *et al.*, *Proc. Natl. Acad. Sci.* 81, 6851-6855, 1984; Neuberger *et al.*, *Nature* 312, 604-608, 1984; Takeda *et al.*, *Nature* 314, 452-454, 1985). Monoclonal and other antibodies also can be "humanized" to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues. Sequence differences between rodent 15 antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grating of entire complementarity determining regions. Alternatively, humanized antibodies can be produced using recombinant methods, as described in GB2188638B. Antibodies which specifically bind to an HM74-like GPCR polypeptide can contain antigen binding sites which are either partially or fully 20 humanized, as disclosed in U.S. 5,565,332.

Alternatively, techniques described for the production of single chain antibodies can be adapted using methods known in the art to produce single chain antibodies which 25 specifically bind to HM74-like GPCR polypeptides. Antibodies with related specificity, but of distinct idiotypic composition, can be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton, *Proc. Natl. Acad. Sci.* 88, 11120-23, 1991).

30 Single-chain antibodies also can be constructed using a DNA amplification method, such as PCR, using hybridoma cDNA as a template (Thirion *et al.*, 1996, *Eur. J.*

Cancer Prev. 5, 507-11). Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain antibodies is taught, for example, in Coloma & Morrison, 1997, *Nat. Biotechnol.* 15, 159-63. Construction of bivalent, bispecific single-chain antibodies is taught in
5 Mallender & Voss, 1994, *J. Biol. Chem.* 269, 199-206.

A nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using standard recombinant DNA methods, and introduced into a cell to express the coding
10 sequence, as described below. Alternatively, single-chain antibodies can be produced directly using, for example, filamentous phage technology (Verhaar *et al.*, 1995, *Int. J. Cancer* 61, 497-501; Nicholls *et al.*, 1993, *J. Immunol. Meth.* 165, 81-91).

15 Antibodies which specifically bind to HM74-like GPCR polypeptides also can be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi *et al.*, *Proc. Natl. Acad. Sci.* 86, 3833-3837, 1989; Winter *et al.*, *Nature* 349, 293-299, 1991).

20 Other types of antibodies can be constructed and used therapeutically in methods of the invention. For example, chimeric antibodies can be constructed as disclosed in WO 93/03151. Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO
25 94/13804, also can be prepared.

Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which an HM74-like GPCR polypeptide is bound. The bound antibodies can then be
30 eluted from the column using a buffer with a high salt concentration.

Antisense Oligonucleotides

Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of HM74-like GPCR gene products in the cell.

Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such as alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters. See Brown, *Meth. Mol. Biol.* 20, 1-8, 1994; Sonveaux, *Meth. Mol. Biol.* 26, 1-72, 1994; Uhlmann *et al.*, *Chem. Rev.* 90, 543-583, 1990. Modifications of HM74-like GPCR gene expression can be obtained by designing antisense oligonucleotides which will form duplexes to the control, 5', or regulatory regions of the HM74-like GPCR. Oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons. Therapeutic advances using triplex DNA have been described in the literature (*e.g.*, Gee *et al.*, in Huber & Carr, MOLECULAR AND IMMUNOLOGIC APPROACHES, Futura Publishing Co., Mt. Kisco,

N.Y., 1994). An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

5 Precise complementarity is not required for successful complex formation between an antisense oligonucleotide and the complementary sequence of an HM74-like GPCR polynucleotide. Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to an HM74-like GPCR polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent HM74-like GPCR
10 nucleotides, can provide sufficient targeting specificity for HM74-like GPCR mRNA. Preferably, each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length. Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in length. One skilled in the art can easily use the calculated melting point of an antisense-sense pair to determine the
15 degree of mismatching which will be tolerated between a particular antisense oligonucleotide and a particular HM74-like GPCR polynucleotide sequence.

Antisense oligonucleotides can be modified without affecting their ability to hybridize to an HM74-like GPCR polynucleotide. These modifications can be
20 internal or at one or both ends of the antisense molecule. For example, internucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose. Modified bases and/or sugars, such as arabinose instead of ribose, or a 3', 5'-substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate
25 group are substituted, also can be employed in a modified antisense oligonucleotide. These modified oligonucleotides can be prepared by methods well known in the art. See, e.g., Agrawal *et al.*, *Trends Biotechnol.* 10, 152-158, 1992; Uhlmann *et al.*, *Chem. Rev.* 90, 543-584, 1990; Uhlmann *et al.*, *Tetrahedron. Lett.* 215, 3539-3542, 1987.

Ribozymes

Ribozymes are RNA molecules with catalytic activity. See, e.g., Cech, *Science* 236, 1532-1539; 1987; Cech, *Ann. Rev. Biochem.* 59, 543-568; 1990, Cech, *Curr. Opin. Struct. Biol.* 2, 605-609; 1992, Couture & Stinchcomb, *Trends Genet.* 12, 510-515, 1996. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art (e.g., Haseloff *et al.*, U.S. Patent 5,641,673). The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences.

The coding sequence of an HM74-like GPCR polynucleotide can be used to generate ribozymes which will specifically bind to mRNA transcribed from the HM74-like GPCR polynucleotide. Methods of designing and constructing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art (see Haseloff *et al.* *Nature* 334, 585-591, 1988). For example, the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme. The hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target (see, for example, Gerlach *et al.*, EP 321,201).

Specific ribozyme cleavage sites within an HM74-like GPCR RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate HM74-like GPCR RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays. Longer

complementary sequences can be used to increase the affinity of the hybridization sequence for the target. The hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.

5

Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease HM74-like GPCR expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art. A ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells.

10
15

As taught in Haseloff *et al.*, U.S. Patent 5,641,673, ribozymes can be engineered so that ribozyme expression will occur in response to factors which induce expression of a target gene. Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.

20

Screening Methods

The invention provides assays for screening test compounds which bind to and/or modulate the activity of an HM74-like GPCR polypeptide or an HM74-like GPCR polynucleotide. A test compound preferably binds to an HM74-like GPCR polypeptide or polynucleotide. More preferably, a test compound decreases or increases a biological effect mediated via human HM74-like GPCR by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the test compound.

25
30

Test Compounds

Test compounds can be pharmacologic agents already known in the art or can be
5 compounds previously unknown to have any pharmacological activity. The
compounds can be naturally occurring or designed in the laboratory. They can be
isolated from microorganisms, animals, or plants, and can be produced re-
combinantly, or synthesized by chemical methods known in the art. If desired, test
compounds can be obtained using any of the numerous combinatorial library
10 methods known in the art, including but not limited to, biological libraries, spatially
addressable parallel solid phase or solution phase libraries, synthetic library methods
requiring deconvolution, the "one-bead one-compound" library method, and
synthetic library methods using affinity chromatography selection. The biological
library approach is limited to polypeptide libraries, while the other four approaches
15 are applicable to polypeptide, non-peptide oligomer, or small molecule libraries of
compounds. See Lam, *Anticancer Drug Des.* 12, 145, 1997.

Methods for the synthesis of molecular libraries are well known in the art (see, for
example, DeWitt *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 90, 6909, 1993; Erb *et al.* *Proc.*
20 *Natl. Acad. Sci. U.S.A.* 91, 11422, 1994; Zuckermann *et al.*, *J. Med. Chem.* 37, 2678,
1994; Cho *et al.*, *Science* 261, 1303, 1993; Carell *et al.*, *Angew. Chem. Int. Ed. Engl.*
33, 2059, 1994; Carell *et al.*, *Angew. Chem. Int. Ed. Engl.* 33, 2061; Gallop *et al.*, *J.*
Med. Chem. 37, 1233, 1994). Libraries of compounds can be presented in solution
(see, e.g., Houghten, *BioTechniques* 13, 412-421, 1992), or on beads (Lam, *Nature*
25 354, 82-84, 1991), chips (Fodor, *Nature* 364, 555-556, 1993), bacteria or spores
(Ladner, U.S. Patent 5,223,409), plasmids (Cull *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*
89, 1865-1869, 1992), or phage (Scott & Smith, *Science* 249, 386-390, 1990; Devlin,
Science 249, 404-406, 1990); Cwirla *et al.*, *Proc. Natl. Acad. Sci.* 97, 6378-6382,
1990; Felici, *J. Mol. Biol.* 222, 301-310, 1991; and Ladner, U.S. Patent 5,223,409).

High Throughput Screening

Test compounds can be screened for the ability to bind to HM74-like GPCR polypeptides or polynucleotides or to affect HM74-like GPCR activity or HM74-like GPCR gene expression using high throughput screening. Using high throughput screening, many discrete compounds can be tested in parallel so that large numbers of test compounds can be quickly screened. The most widely established techniques utilize 96-well microtiter plates. The wells of the microtiter plates typically require assay volumes that range from 50 to 500 μ l. In addition to the plates, many instruments, materials, pipettors, robotics, plate washers, and plate readers are commercially available to fit the 96-well format.

Alternatively, "free format assays," or assays that have no physical barrier between samples, can be used. For example, an assay using pigment cells (melanocytes) in a simple homogeneous assay for combinatorial peptide libraries is described by Jayawickreme *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 19, 1614-18 (1994). The cells are placed under agarose in petri dishes, then beads that carry combinatorial compounds are placed on the surface of the agarose. The combinatorial compounds are partially released the compounds from the beads. Active compounds can be visualized as dark pigment areas because, as the compounds diffuse locally into the gel matrix, the active compounds cause the cells to change colors.

Another example of a free format assay is described by Chelsky, "Strategies for Screening Combinatorial Libraries: Novel and Traditional Approaches," reported at the First Annual Conference of The Society for Biomolecular Screening in Philadelphia, Pa. (Nov. 7-10, 1995). Chelsky placed a simple homogenous enzyme assay for carbonic anhydrase inside an agarose gel such that the enzyme in the gel would cause a color change throughout the gel. Thereafter, beads carrying combinatorial compounds via a photolinker were placed inside the gel and the compounds were partially released by UV-light. Compounds that inhibited the enzyme were observed as local zones of inhibition having less color change.

Yet another example is described by Salmon *et al.*, *Molecular Diversity* 2, 57-63 (1996). In this example, combinatorial libraries were screened for compounds that had cytotoxic effects on cancer cells growing in agar.

5

Another high throughput screening method is described in Beutel *et al.*, U.S. Patent 5,976,813. In this method, test samples are placed in a porous matrix. One or more assay components are then placed within, on top of, or at the bottom of a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support.

10

When samples are introduced to the porous matrix they diffuse sufficiently slowly, such that the assays can be performed without the test samples running together.

Binding Assays

15

For binding assays, the test compound is preferably a small molecule which binds to and occupies the active site of the HM74-like GPCR polypeptide, thereby making the ligand binding site inaccessible to substrate such that normal biological activity is prevented. Examples of such small molecules include, but are not limited to, small peptides or peptide-like molecules. Potential ligands which may bind to a polypeptide of the invention include, but are not limited to, the natural ligands of known GPCRs and analogues or derivatives thereof. Natural ligands of GPCRs include, for example, adrenomedullin, amylin, calcitonin gene related protein (CGRP), calcitonin, anandamide, serotonin, histamine, adrenalin, noradrenalin, platelet activating factor, thrombin, C5a, bradykinin, and chemokines.

20

25

In binding assays, either the test compound or the HM74-like GPCR polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase. Detection of a test compound which is bound to the HM74-like GPCR polypeptide can then be accomplished, for example, by direct counting of

30

radioemmission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product.

Alternatively, binding of a test compound to an HM74-like GPCR polypeptide can be determined without labeling either of the interactants. For example, a microphysiometer can be used to detect binding of a test compound with an HM74-like GPCR polypeptide. A microphysiometer (e.g., Cytosensor™) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a test compound and an HM74-like GPCR polypeptide (McConnell *et al.*, *Science* 257, 1906-1912, 1992).

Determining the ability of a test compound to bind to an HM74-like GPCR polypeptide also can be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) (Sjolander & Urbaniczky, *Anal. Chem.* 63, 2338-2345, 1991, and Szabo *et al.*, *Curr. Opin. Struct. Biol.* 5, 699-705, 1995). BIA is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore™). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In yet another aspect of the invention, an HM74-like GPCR polypeptide can be used as a "bait protein" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent 5,283,317; Zervos *et al.*, *Cell* 72, 223-232, 1993; Madura *et al.*, *J. Biol. Chem.* 268, 12046-12054, 1993; Bartel *et al.*, *BioTechniques* 14, 920-924, 1993; Iwabuchi *et al.*, *Oncogene* 8, 1693-1696, 1993; and Brent W094/10300), to identify other proteins which bind to or interact with the HM74-like GPCR polypeptide and modulate its activity.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay

utilizes two different DNA constructs. For example, in one construct, polynucleotide encoding an HM74-like GPCR polypeptide can be fused to a polynucleotide encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct a DNA sequence that encodes an unidentified protein ("prey" or "sample") can be fused to a polynucleotide that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact *in vivo* to form an protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ), which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein which interacts with the HM74-like GPCR polypeptide.

It may be desirable to immobilize either the HM74-like GPCR polypeptide (or polynucleotide) or the test compound to facilitate separation of bound from unbound forms of one or both of the interactants, as well as to accommodate automation of the assay. Thus, either the HM74-like GPCR polypeptide (or polynucleotide) or the test compound can be bound to a solid support. Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art can be used to attach the HM74-like GPCR polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide) or test compound and the solid support. Test compounds are preferably bound to the solid support in an array, so that the location of individual test compounds can be tracked. Binding of a test compound to an HM74-like GPCR polypeptide (or polynucleotide) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.

In one embodiment, the HM74-like GPCR polypeptide is a fusion protein comprising a domain that allows the HM74-like GPCR polypeptide to be bound to a solid support. For example, glutathione-S-transferase fusion proteins can be adsorbed onto
5 glutathione sepharose beads (Sigma Chemical) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and the non-adsorbed HM74-like GPCR polypeptide; the mixture is then incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to
10 remove any unbound components. Binding of the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined.

Other techniques for immobilizing proteins or polynucleotides on a solid support also
15 can be used in the screening assays of the invention. For example, either an HM74-like GPCR polypeptide (or polynucleotide) or a test compound can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated HM74-like GPCR polypeptides (or polynucleotides) or test compounds can be prepared from biotin-NHS(N-hydroxysuccinimide) using techniques well known in the art (*e.g.*,
20 biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies which specifically bind to an HM74-like GPCR polypeptide, polynucleotide, or a test compound, but which do not interfere with a desired binding site, such as the active site of the HM74-like GPCR polypeptide, can be derivatized to the wells of the plate.
25 Unbound target or protein can be trapped in the wells by antibody conjugation.

Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies which specifically bind to the HM74-like GPCR polypeptide or test
30 compound, enzyme-linked assays which rely on detecting an activity of the HM74-like GPCR polypeptide, and SDS gel electrophoresis under non-reducing conditions.

Screening for test compounds which bind to an HM74-like GPCR polypeptide or polynucleotide also can be carried out in an intact cell. Any cell which comprises an HM74-like GPCR polypeptide or polynucleotide can be used in a cell-based assay system. An HM74-like GPCR polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Binding of the test compound to an HM74-like GPCR polypeptide or polynucleotide is determined as described above.

10 Functional Assays

Test compounds can be tested for the ability to increase or decrease a biological effect of an HM74-like GPCR polypeptide. Such biological effects can be determined using functional assays such as those described in the specific examples, below. Functional assays can be carried out after contacting either a purified HM74-like GPCR polypeptide, a cell membrane preparation, or an intact cell with a test compound. A test compound which decreases an activity of an HM74-like GPCR by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential therapeutic agent for decreasing HM74-like GPCR activity. A test compound which increases an HM74-like GPCR activity by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential therapeutic agent for increasing HM74-like GPCR activity.

One such screening procedure involves the use of melanophores which are transfected to express an HM74-like GPCR polypeptide. Such a screening technique is described in WO 92/01810 published Feb. 6, 1992. Thus, for example, such an assay may be employed for screening for a compound which inhibits activation of the receptor polypeptide by contacting the melanophore cells which comprise the receptor with both a receptor ligand and a test compound to be screened. Inhibition of the signal generated by the ligand indicates that a test compound is a potential antagonist for the receptor, *i.e.*, inhibits activation of the receptor. The screen may be

employed for identifying a test compound which activates the receptor by contacting such cells with compounds to be screened and determining whether each test compound generates a signal, *i.e.*, activates the receptor.

- 5 Other screening techniques include the use of cells which express a human HM74-like GPCR polypeptide (for example, transfected CHO cells) in a system which measures extracellular pH changes caused by receptor activation (*see, e.g., Science* 246, 181-296, 1989). For example, test compounds may be contacted with a cell which expresses a human HM74-like GPCR polypeptide and a second messenger
10 response, *e.g.*, signal transduction or pH changes, can be measured to determine whether the test compound activates or inhibits the receptor.

- Another such screening technique involves introducing RNA encoding a human HM74-like GPCR polypeptide into *Xenopus* oocytes to transiently express the
15 receptor. The transfected oocytes can then be contacted with the receptor ligand and a test compound to be screened, followed by detection of inhibition or activation of a calcium signal in the case of screening for test compounds which are thought to inhibit activation of the receptor.

- 20 Another screening technique involves expressing a human HM74-like GPCR polypeptide in cells in which the receptor is linked to a phospholipase C or D. Such cells include endothelial cells, smooth muscle cells, embryonic kidney cells, etc. The screening may be accomplished as described above by quantifying the degree of activation of the receptor from changes in the phospholipase activity.

- 25 Details of functional assays such as those described above are provided in the specific examples, below.

Gene Expression

In another embodiment, test compounds which increase or decrease HM74-like GPCR gene expression are identified. An HM74-like GPCR polynucleotide is contacted with a test compound, and the expression of an RNA or polypeptide product of the HM74-like GPCR polynucleotide is determined. The level of expression of appropriate mRNA or polypeptide in the presence of the test compound is compared to the level of expression of mRNA or polypeptide in the absence of the test compound. The test compound can then be identified as a modulator of expression based on this comparison. For example, when expression of mRNA or polypeptide is greater in the presence of the test compound than in its absence, the test compound is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively, when expression of the mRNA or polypeptide is less in the presence of the test compound than in its absence, the test compound is identified as an inhibitor of the mRNA or polypeptide expression.

The level of HM74-like GPCR mRNA or polypeptide expression in the cells can be determined by methods well known in the art for detecting mRNA or polypeptide. Either qualitative or quantitative methods can be used. The presence of polypeptide products of an HM74-like GPCR polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry. Alternatively, polypeptide synthesis can be determined *in vivo*, in a cell culture, or in an *in vitro* translation system by detecting incorporation of labeled amino acids into an HM74-like GPCR polypeptide.

Such screening can be carried out either in a cell-free assay system or in an intact cell. Any cell which expresses an HM74-like GPCR polynucleotide can be used in a cell-based assay system. The HM74-like GPCR polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described

above. Either a primary culture or an established cell line, such as CHO or human embryonic kidney 293 cells, can be used.

Pharmaceutical Compositions

5

The invention also provides pharmaceutical compositions which can be administered to a patient to achieve a therapeutic effect. Pharmaceutical compositions of the invention can comprise, for example, an HM74-like GPCR polypeptide, HM74-like GPCR polynucleotide, antibodies which specifically bind to an HM74-like GPCR polypeptide, or mimetics, agonists, antagonists, or inhibitors of an HM74-like GPCR polypeptide activity. The compositions can be administered alone or in combination with at least one other agent, such as stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.

15

20

25

In addition to the active ingredients, these pharmaceutical compositions can contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Pharmaceutical compositions of the invention can be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means. Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

30

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally,

suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers also can be used for delivery. Optionally, the suspension also can contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

10

The pharmaceutical compositions of the present invention can be manufactured in a manner that is known in the art, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. The pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation can be a lyophilized powder which can contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

15

20

Further details on techniques for formulation and administration can be found in the latest edition of REMINGTON'S PHARMACEUTICAL SCIENCES (Maack Publishing Co., Easton, Pa.). After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.

25

Therapeutic Indications and Methods

GPCRs are ubiquitous in the mammalian host and are responsible for many biological functions, including many pathologies. Accordingly, it is desirable to find compounds and drugs which stimulate a GPCR on the one hand and which can inhibit the function of a GPCR on the other hand. For example, compounds which activate a GPCR may be employed for therapeutic purposes, such as the treatment of asthma, inflammation, CNS disorders, including Parkinson's disease, acute heart failure, urinary retention, and osteoporosis. In particular, compounds which activate GPCRs are useful in treating various cardiovascular ailments such as caused by the lack of pulmonary blood flow or hypertension. In addition these compounds may also be used in treating various physiological disorders relating to abnormal control of fluid and electrolyte homeostasis and in diseases associated with abnormal angiotensin-induced aldosterone secretion.

In general, compounds which inhibit activation of a GPCR can be used for a variety of therapeutic purposes, for example, for the treatment of hypotension and/or hypertension, angina pectoris, myocardial infarction, inflammation, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders including schizophrenia, manic excitement, depression, delirium, dementia or severe mental retardation, dyskinesias, such as Huntington's disease or Tourett's syndrome, among others. Compounds which inhibit GPCRs also are useful in reversing endogenous anorexia and in the control of bulimia.

Cancer. Human HM74-like GPCR may be useful for treating cancer. Cancer is a disease fundamentally caused by oncogenic cellular transformation. There are several hallmarks of transformed cells that distinguish them from their normal counterparts and underlie the pathophysiology of cancer. These include uncontrolled cellular proliferation, unresponsiveness to normal death-inducing signals (immortalization), increased cellular motility and invasiveness, increased ability to recruit blood supply through induction of new blood vessel formation (angiogenesis),

genetic instability, and dysregulated gene expression. Various combinations of these aberrant physiologies, along with the acquisition of drug-resistance frequently lead to an intractable disease state in which organ failure and patient death ultimately ensue.

5 Most standard cancer therapies target cellular proliferation and rely on the differential proliferative capacities between transformed and normal cells for their efficacy. This approach is hindered by the facts that several important normal cell types are also highly proliferative and that cancer cells frequently become resistant to these agents. Thus, the therapeutic indices for traditional anti-cancer therapies rarely
10 exceed 2.0.

The advent of genomics-driven molecular target identification has opened up the possibility of identifying new cancer-specific targets for therapeutic intervention that will provide safer, more effective treatments for cancer patients. Thus, newly
15 discovered tumor-associated genes and their products can be tested for their role(s) in disease and used as tools to discover and develop innovative therapies. Genes playing important roles in any of the physiological processes outlined above can be characterized as cancer targets.

20 Genes or gene fragments identified through genomics can readily be expressed in one or more heterologous expression systems to produce functional recombinant proteins. These proteins are characterized *in vitro* for their biochemical properties and then used as tools in high-throughput molecular screening programs to identify chemical modulators of their biochemical activities. Agonists and/or antagonists of target
25 protein activity can be identified in this manner and subsequently tested in cellular and *in vivo* disease models for anti-cancer activity. Optimization of lead compounds with iterative testing in biological models and detailed pharmacokinetic and toxicological analyses form the basis for drug development and subsequent testing in humans.

30

Diabetes. Human HM74-like GPCR also may be useful for treating diabetes. Diabetes mellitus is a common metabolic disorder characterized by an abnormal elevation in blood glucose, alterations in lipids and abnormalities (complications) in the cardiovascular system, eye, kidney and nervous system. Diabetes is divided into
5 two separate diseases: type 1 diabetes (juvenile onset) that results from a loss of cells which make and secrete insulin, and type 2 diabetes (adult onset) which is caused by a defect in insulin secretion and a defect in insulin action.

Type 1 diabetes is initiated by an autoimmune reaction that attacks the insulin
10 secreting cells (beta cells) in the pancreatic islets. Agents that prevent this reaction from occurring or that stop the reaction before destruction of the beta cells has been accomplished are potential therapies for this disease. Other agents that induce beta cell proliferation and regeneration are also potential therapies.

15 Type II diabetes is the most common of the two diabetic conditions (6% of the population). The defect in insulin secretion is an important cause of the diabetic condition and results from an inability of the beta cell to properly detect and respond to rises in blood glucose levels with insulin release. Therapies that increase the
20 response by the beta cell to glucose would offer an important new treatment for this disease.

The defect in insulin action in Type II diabetic subjects is another target for therapeutic intervention. Agents that increase the activity of the insulin receptor in muscle, liver and fat will cause a decrease in blood glucose and a normalization of
25 plasma lipids. The receptor activity can be increased by agents that directly stimulate the receptor or that increase the intracellular signals from the receptor. Other therapies can directly activate the cellular end process, *i.e.* glucose transport or various enzyme systems, to generate an insulin-like effect and therefore produce
30 beneficial outcome. Because overweight subjects have a greater susceptibility to Type II diabetes, any agent that reduces body weight is a possible therapy.

Both Type I and Type diabetes can be treated with agents that mimic insulin action or that treat diabetic complications by reducing blood glucose levels. Likewise agents that reduces new blood vessel growth can be used to treat the eye complications that develop in both diseases.

5

Obesity. Human HM74-like GPCR also may be used to treat obesity and other eating disorders. Obesity and overweight are defined as an excess of body fat relative to lean body mass. An increase in caloric intake or a decrease in energy expenditure or both can bring about this imbalance leading to surplus energy being stored as fat. Obesity is associated with important medical morbidities and an increase in mortality. The causes of obesity are poorly understood and may be due to genetic factors, environmental factors or a combination of the two to cause a positive energy balance. In contrast, anorexia and cachexia are characterized by an imbalance in energy intake versus energy expenditure leading to a negative energy balance and weight loss. Agents that either increase energy expenditure and/or decrease energy intake, absorption or storage would be useful for treating obesity, overweight, and associated comorbidities. Agents that either increase energy intake and/or decrease energy expenditure or increase the amount of lean tissue would be useful for treating cachexia, anorexia and wasting disorders.

10

15

20

25

30

The human HM74-like GPCR gene, translated proteins, and agents which modulate the human HM74-like gene or portions of the gene or its products are useful for treating obesity, overweight, anorexia, cachexia, wasting disorders, appetite suppression, appetite enhancement, increases or decreases in satiety, modulation of body weight, and/or other eating disorders such as bulimia. Also this gene, translated proteins and agents which modulate this gene or portions of the gene or its products are useful for treating obesity/overweight-associated comorbidities including hypertension; type 2 diabetes; coronary artery disease; hyperlipidemia; stroke; gallbladder disease; gout; osteoarthritis; sleep apnea and respiratory problems; some types of cancer including endometrial, breast, prostate and colon; thrombotic disease;

polycystic ovarian syndrome; reduced fertility; complications of pregnancy; menstrual irregularities; hirsutism; stress incontinence and depression.

5 Osteoporosis. Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk. It is the most common human metabolic bone disorder. Established osteoporosis includes the presence of fractures.

10 Bone turnover occurs by the action of two major effector cell types within bone: the osteoclast, which is responsible for bone resorption, and the osteoblast, which synthesizes and mineralizes bone matrix. The actions of osteoclasts and osteoblasts are highly coordinated. Osteoclast precursors are recruited to the site of turnover; they differentiate and fuse to form mature osteoclasts which then resorb bone. Attached to the bone surface, osteoclasts produce an acidic microenvironment in a
15 tightly defined junction between the specialized osteoclast border membrane and the bone matrix, thus allowing the localized solubilization of bone matrix. This in turn facilitates the proteolysis of demineralized bone collagen. Matrix degradation is thought to release matrix-associated growth factor and cytokines, which recruit osteoblasts in a temporally and spatially controlled fashion. Osteoblasts synthesize
20 and secrete new bone matrix proteins, and subsequently mineralize this new matrix. In the normal skeleton this is a physiological process which does not result in a net change in bone mass. In pathological states, such as osteoporosis, the balance between resorption and formation is altered such that bone loss occurs. See WO 99/45923.

25 The osteoclast itself is the direct or indirect target of all currently available osteoporosis agents with the possible exception of fluoride. Antiresorptive therapy prevents further bone loss in treated individuals. Osteoblasts are derived from multipotent stem cells which reside in bone marrow and also gives rise to adipocytes,
30 chondrocytes, fibroblasts and muscle cells. Selective enhancement of osteoblast activity is a highly desirable goal for osteoporosis therapy since it would result in an

increase in bone mass, rather than a prevention of further bone loss. An effective anabolic therapy would be expected to lead to a significantly greater reduction in fracture risk than currently available treatments.

5 The agonists or antagonists to the newly discovered polypeptides may act as antiresorptive by directly altering the osteoclast differentiation, osteoclast adhesion to the bone matrix or osteoclast function of degrading the bone matrix. The agonists or antagonists could indirectly alter the osteoclast function by interfering in the synthesis and/or modification of effector molecules of osteoclast differentiation or
10 function such as cytokines, peptide or steroid hormones, proteases, etc.

The agonists or antagonists to the newly discovered polypeptides may act as anabolics by directly enhancing the osteoblast differentiation and /or its bone matrix forming function. The agonists or antagonists could also indirectly alter the
15 osteoblast function by enhancing the synthesis of growth factors, peptide or steroid hormones or decreasing the synthesis of inhibitory molecules.

The agonists and antagonists may be used to mimic, augment or inhibit the action of the newly discovered polypeptides which may be useful to treat osteoporosis, Paget's
20 disease, degradation of bone implants particularly dental implants.

Liver fibrosis. Liver fibrosis pathogenesis involves altered proliferation and gene expression of multiple cell types, such as hepatic stellate cells and cholangiocytes. These changes cause altered collagen content and altered connective tissue
25 deposition, water retention, cholestasis, etc. Many ligand-receptor interactions are involved in these changes. Among the ligands are vasopressin, secretin, vasoactive intestinal peptide, etc., all of which use GPCR-mediated signal transduction pathways. Thus, human HM74-like GPCR is a potential target for therapeutic intervention in liver fibrosis.

Cardiovascular Disease. Many GPCRs are involved in cardiovascular diseases; thus, human HM74-like GPCR is a potential target for therapeutic intervention in cardiovascular diseases, such as congestive heart failure, myocardial infarction, ischemic diseases of the heart, all kinds of atrial and ventricular arrhythmias, hypertensive vascular diseases and peripheral vascular diseases.

Heart failure is defined as a pathophysiologic state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirement of the metabolizing tissue. It includes all forms of pumping failure such as high-output and low-output, acute and chronic, right-sided or left-sided, systolic or diastolic, independent of the underlying cause.

Myocardial infarction (MI) is generally caused by an abrupt decrease in coronary blood flow that follows a thrombotic occlusion of a coronary artery previously narrowed by arteriosclerosis. MI prophylaxis (primary and secondary prevention) is included as well as the acute treatment of MI and the prevention of complications.

Ischemic diseases are conditions in which the coronary flow is restricted resulting in an perfusion which is inadequate to meet the myocardial requirement for oxygen. This group of diseases include stable angina, unstable angina and asymptomatic ischemia.

Arrhythmias include all forms of atrial and ventricular tachyarrhythmias (atrial tachycardia, atrial flutter, atrial fibrillation, atrio-ventricular reentrant tachycardia, preexcitation syndrome, ventricular tachycardia, ventricular flutter, ventricular fibrillation) as well as bradycardic forms of arrhythmias.

Hypertensive vascular diseases include primary as well as all kinds of secondary arterial hypertension (renal, endocrine, neurogenic, others). The genes may be used as drug targets for the treatment of hypertension as well as for the prevention of all complications. Peripheral vascular diseases are defined as vascular diseases in which

arterial and/or venous flow is reduced resulting in an imbalance between blood supply and tissue oxygen demand. It includes chronic peripheral arterial occlusive disease (PAOD), acute arterial thrombosis and embolism, inflammatory vascular disorders, Raynaud's phenomenon and venous disorders.

5

This invention further pertains to the use of novel agents identified by the screening assays described above. Accordingly, it is within the scope of this invention to use a test compound identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a modulating agent, an
10 antisense nucleic acid molecule, a specific antibody, ribozyme, or an HM74-like GPCR polypeptide binding molecule) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to
15 uses of novel agents identified by the above-described screening assays for treatments as described herein.

A reagent which affects HM74-like GPCR activity can be administered to a human cell, either *in vitro* or *in vivo*, to reduce HM74-like GPCR activity. The reagent
20 preferably binds to an expression product of a human HM74-like GPCR gene. If the expression product is a protein, the reagent is preferably an antibody. For treatment of human cells *ex vivo*, an antibody can be added to a preparation of stem cells which have been removed from the body. The cells can then be replaced in the same or another human body, with or without clonal propagation, as is known in the art.

25

In one embodiment, the reagent is delivered using a liposome. Preferably, the liposome is stable in the animal into which it has been administered for at least about 30 minutes, more preferably for at least about 1 hour, and even more preferably for at least about 24 hours. A liposome comprises a lipid composition that is capable of
30 targeting a reagent, particularly a polynucleotide, to a particular site in an animal, such as a human. Preferably, the lipid composition of the liposome is capable of

targeting to a specific organ of an animal, such as the lung, liver, spleen, heart brain, lymph nodes, and skin.

5 A liposome useful in the present invention comprises a lipid composition that is capable of fusing with the plasma membrane of the targeted cell to deliver its contents to the cell. Preferably, the transfection efficiency of a liposome is about 0.5 μg of DNA per 16 nmole of liposome delivered to about 10^6 cells, more preferably about 1.0 μg of DNA per 16 nmole of liposome delivered to about 10^6 cells, and even more preferably about 2.0 μg of DNA per 16 nmol of liposome
10 delivered to about 10^6 cells. Preferably, a liposome is between about 100 and 500 nm, more preferably between about 150 and 450 nm, and even more preferably between about 200 and 400 nm in diameter.

15 Suitable liposomes for use in the present invention include those liposomes standardly used in, for example, gene delivery methods known to those of skill in the art. More preferred liposomes include liposomes having a polycationic lipid composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol. Optionally, a liposome comprises a compound capable of targeting the liposome to a particular cell types, such as a cell-specific ligand
20 exposed on the outer surface of the liposome.

Complexing a liposome with a reagent such as an antisense oligonucleotide or ribozyme can be achieved using methods which are standard in the art (see, for example, U.S. Patent 5,705,151). Preferably, from about 0.1 μg to about 10 μg of
25 polynucleotide is combined with about 8 nmol of liposomes, more preferably from about 0.5 μg to about 5 μg of polynucleotides are combined with about 8 nmol liposomes, and even more preferably about 1.0 μg of polynucleotides is combined with about 8 nmol liposomes.

30 In another embodiment, antibodies can be delivered to specific tissues *in vivo* using receptor-mediated targeted delivery. Receptor-mediated DNA delivery techniques

are taught in, for example, Findeis *et al.* *Trends in Biotechnol.* 11, 202-05 (1993); Chiou *et al.*, GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER (J.A. Wolff, ed.) (1994); Wu & Wu, *J. Biol. Chem.* 263, 621-24 (1988); Wu *et al.*, *J. Biol. Chem.* 269, 542-46 (1994); Zenke *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 87, 3655-59 (1990); Wu *et al.*, *J. Biol. Chem.* 266, 338-42 (1991).

Determination of a Therapeutically Effective Dose

The determination of a therapeutically effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient which increases or decreases HM74-like GPCR activity relative to the HM74-like GPCR activity which occurs in the absence of the therapeutically effective dose.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

Therapeutic efficacy and toxicity, *e.g.*, ED₅₀ (the dose therapeutically effective in 50% of the population) and LD₅₀ (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD₅₀/ED₅₀.

Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED₅₀ with

little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

5 The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect. Factors which can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and
10 tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation. Normal dosage amounts can vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of
15 delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

20 If the reagent is a single-chain antibody, polynucleotides encoding the antibody can be constructed and introduced into a cell either *ex vivo* or *in vivo* using well-established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads,
25 protoplast fusion, viral infection, electroporation, "gene gun," and DEAE- or calcium phosphate-mediated transfection.

Effective *in vivo* dosages of an antibody are in the range of about 5 μg to about 50 $\mu\text{g}/\text{kg}$, about 50 μg to about 5 mg/kg , about 100 μg to about 500 $\mu\text{g}/\text{kg}$ of patient
30 body weight, and about 200 to about 250 $\mu\text{g}/\text{kg}$ of patient body weight. For administration of polynucleotides encoding single-chain antibodies, effective *in vivo*

dosages are in the range of about 100 ng to about 200 ng, 500 ng to about 50 mg, about 1 μ g to about 2 mg, about 5 μ g to about 500 μ g, and about 20 μ g to about 100 μ g of DNA.

- 5 If the expression product is mRNA, the reagent is preferably an antisense oligonucleotide or a ribozyme. Polynucleotides which express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above.
- 10 Preferably, a reagent reduces expression of an HM74-like GPCR gene or the activity of an HM74-like GPCR polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of expression of an HM74-like GPCR gene or the activity of an HM74-like GPCR polypeptide can be
- 15 assessed using methods well known in the art, such as hybridization of nucleotide probes to HM74-like GPCR-specific mRNA, quantitative RT-PCR, immunologic detection of an HM74-like GPCR polypeptide, or measurement of HM74-like GPCR activity.
- 20 In any of the embodiments described above, any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents can act
- 25 synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
- Any of the therapeutic methods described above can be applied to any subject in
- 30 need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

Diagnostic Methods

GPCRs also can be used in diagnostic assays for detecting diseases and abnormalities or susceptibility to diseases and abnormalities related to the presence of mutations in the nucleic acid sequences which encode a GPCR. Such diseases, by way of example, are related to cell transformation, such as tumors and cancers, and various cardiovascular disorders, including hypertension and hypotension, as well as diseases arising from abnormal blood flow, abnormal angiotensin-induced aldosterone secretion, and other abnormal control of fluid and electrolyte homeostasis.

According to the present invention, differences can be determined between the cDNA or genomic sequence encoding HM74-like GPCR in individuals afflicted with a disease and in normal individuals. If a mutation is observed in some or all of the afflicted individuals but not in normal individuals, then the mutation is likely to be the causative agent of the disease.

Sequence differences between a reference gene and a gene having mutations can be revealed by the direct DNA sequencing method. In addition, cloned DNA segments can be employed as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. For example, a sequencing primer can be used with a double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures using radiolabeled nucleotides or by automatic sequencing procedures using fluorescent tags.

Genetic testing based on DNA sequence differences can be carried out by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized, for example, by high resolution gel electrophoresis. DNA fragments of different sequences can be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions

according to their specific melting or partial melting temperatures (*see, e.g., Myers et al., Science 230, 1242, 1985*). Sequence changes at specific locations can also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (*e.g., Cotton et al., Proc. Natl. Acad. Sci. USA 85, 4397-4401, 1985*). Thus, the detection of a specific DNA sequence can be performed by methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes and Southern blotting of genomic DNA. In addition to direct methods such as gel-electrophoresis and DNA sequencing, mutations can also be detected by *in situ* analysis.

Altered levels of an HM74-like GPCR also can be detected in various tissues. Assays used to detect levels of the receptor polypeptides in a body sample, such as blood or a tissue biopsy, derived from a host are well known to those of skill in the art and include radioimmunoassays, competitive binding assays, Western blot analysis, and ELISA assays.

All patents and patent applications cited in this disclosure are expressly incorporated herein by reference. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided for purposes of illustration only and are not intended to limit the scope of the invention.

EXAMPLE 1*Detection of HM74-like GPCR activity*

5 The polynucleotide of SEQ ID NO. 1 is inserted into the expression vector pCEV4 and the expression vector pCEV4-HM74-like GPCR polypeptide obtained is transfected into human embryonic kidney 293 cells. The cells are scraped from a culture flask into 5 ml of Tris HCl, 5 mM EDTA, pH 7.5, and lysed by sonication. Cell lysates are centrifuged at 1000 rpm for 5 minutes at 4°C. The supernatant is
10 centrifuged at 30,000 x g for 20 minutes at 4°C. The pellet is suspended in binding buffer containing 50 mM Tris HCl, 5 mM MgSO₄, 1 mM EDTA, 100 mM NaCl, pH 7.5, supplemented with 0.1 % BSA, 2 µg/ml aprotinin, 0.5 mg/ml leupeptin, and 10 µg/ml phosphoramidon. Optimal membrane suspension dilutions, defined as the protein concentration required to bind less than 10 % of an added radioligand, i.e.
15 ¹²⁵I-labeled HM74, are added to 96-well polypropylene microtiter plates containing ligand, non-labeled peptides, and binding buffer to a final volume of 250 µl.

In equilibrium saturation binding assays, membrane preparations are incubated in the presence of increasing concentrations (0.1 nM to 4 nM) of ¹²⁵I ligand.

20 Binding reaction mixtures are incubated for one hour at 30°C. The reaction is stopped by filtration through GF/B filters treated with 0.5% polyethyleneimine, using a cell harvester. Radioactivity is measured by scintillation counting, and data are analyzed by a computerized non-linear regression program. Non-specific binding is
25 defined as the amount of radioactivity remaining after incubation of membrane protein in the presence of 100 nM of unlabeled peptide. Protein concentration is measured by the Bradford method using Bio-Rad Reagent, with bovine serum albumin as a standard. The HM74-like GPCR activity of the polypeptide comprising the amino acid sequence of SEQ ID NO. 2 is demonstrated

30

EXAMPLE 2

Expression of recombinant human HM74-like GPCR

5 The *Pichia pastoris* expression vector pPICZB (Invitrogen, San Diego, CA) is used to produce large quantities of a human HM74-like GPCR polypeptides in yeast. The human HM74-like GPCR polypeptide-encoding DNA sequence is derived from the nucleotide sequence shown in SEQ ID NO. 3. Before insertion into vector pPICZB the DNA sequence is modified by well known methods in such a way that it contains
10 at its 5'-end an initiation codon and at its 3'-end an enterokinase cleavage site, a His6 reporter tag and a termination codon. Moreover, at both termini recognition sequences for restriction endonucleases are added and after digestion of the multiple cloning site of pPICZ B with the corresponding restriction enzymes the modified polypeptide encoding DNA sequence is ligated into pPICZB. This expression vector
15 is designed for inducible expression in *Pichia pastoris*, expression is driven by a yeast promoter. The resulting pPICZ/md-His6 vector is used to transform the yeast.

The yeast are cultivated under usual conditions in 5 liter shake flasks and the recombinantly produced protein isolated from the culture by affinity chromatography
20 (Ni-NTA-Resin) in the presence of 8 M urea. The bound polypeptide is eluted with buffer, pH 3.5, and neutralized. Separation of the HM74-like GPCR polypeptide from the His6 reporter tag is accomplished by site-specific proteolysis using enterokinase (Invitrogen, San Diego, CA) according to manufacturer's instructions. Purified human HM74-like GPCR polypeptide is obtained.

25

EXAMPLE 3

Radioligand binding assays

30 Human embryonic kidney 293 cells transfected with a polynucleotide which expresses human HM74-like GPCR are scraped from a culture flask into 5 ml of Tris HCl, 5 mM EDTA, pH 7.5, and lysed by sonication. Cell lysates are centrifuged at 1000 rpm for 5 minutes at 4°C. The supernatant is centrifuged at 30,000 x g for 20

minutes at 4°C. The pellet is suspended in binding buffer containing 50 mM Tris HCl, 5 mM MgSO₄, 1 mM EDTA, 100 mM NaCl, pH 7.5, supplemented with 0.1 % BSA, 2 µg/ml aprotinin, 0.5 mg/ml leupeptin, and 10 µg/ml phosphoramidon. Optimal membrane suspension dilutions, defined as the protein concentration
5 required to bind less than 10 % of the added radioligand, i.e. HM74, are added to 96-well polypropylene microtiter plates containing ¹²⁵I-labeled ligand or test compound, non-labeled peptides, and binding buffer to a final volume of 250 µl.

In equilibrium saturation binding assays, membrane preparations are incubated in the
10 presence of increasing concentrations (0.1 nM to 4 nM) of ¹²⁵I-labeled ligand or test compound (specific activity 2200 Ci/mmol). The binding affinities of different test compounds are determined in equilibrium competition binding assays, using 0.1 nM ¹²⁵I-peptide in the presence of twelve different concentrations of each test compound.

15 Binding reaction mixtures are incubated for one hour at 30°C. The reaction is stopped by filtration through GF/B filters treated with 0.5% polyethyleneimine, using a cell harvester. Radioactivity is measured by scintillation counting, and data are analyzed by a computerized non-linear regression program.

20 Non-specific binding is defined as the amount of radioactivity remaining after incubation of membrane protein in the presence of 100 nM of unlabeled peptide. Protein concentration is measured by the Bradford method using Bio-Rad Reagent, with bovine serum albumin as a standard. A test compound which increases the
25 radioactivity of membrane protein by at least 15% relative to radioactivity of membrane protein which was not incubated with a test compound is identified as a compound which binds to a human HM74-like GPCR polypeptide.

EXAMPLE 4

Effect of a test compound on human HM74-like GPCR-mediated cyclic AMP formation

5

Receptor-mediated inhibition of cAMP formation can be assayed in host cells which express human HM74-like GPCR. Cells are plated in 96-well plates and incubated in Dulbecco's phosphate buffered saline (PBS) supplemented with 10 mM HEPES, 5 mM theophylline, 2 µg/ml aprotinin, 0.5 mg/ml leupeptin, and 10 µg/ml phosphoramidon for 20 minutes at 37°C in 5% CO₂. A test compound is added and incubated for an additional 10 minutes at 37°C. The medium is aspirated, and the reaction is stopped by the addition of 100 mM HCl. The plates are stored at 4°C for 15 minutes. cAMP content in the stopping solution is measured by radioimmunoassay.

15

Radioactivity is quantified using a gamma counter equipped with data reduction software. A test compound which decreases radioactivity of the contents of a well relative to radioactivity of the contents of a well in the absence of the test compound is identified as a potential inhibitor of cAMP formation. A test compound which increases radioactivity of the contents of a well relative to radioactivity of the contents of a well in the absence of the test compound is identified as a potential enhancer of cAMP formation.

20

EXAMPLE 5

25

Effect of a test compound on the mobilization of intracellular calcium

Intracellular free calcium concentration can be measured by microspectrofluorometry using the fluorescent indicator dye Fura-2/AM (Bush *et al.*, *J. Neurochem.* 57, 562-74, 1991). Stably transfected cells are seeded onto a 35 mm culture dish containing a glass coverslip insert. Cells are washed with HBS, incubated with a test compound, and loaded with 100 µl of Fura-2/AM (10 µM) for 20-40 minutes. After washing

30

with HBS to remove the Fura-2/AM solution, cells are equilibrated in HBS for 10-20 minutes. Cells are then visualized under the 40X objective of a Leitz Fluovolt FS microscope.

- 5 Fluorescence emission is determined at 510 nM, with excitation wavelengths alternating between 340 nM and 380 nM. Raw fluorescence data are converted to calcium concentrations using standard calcium concentration curves and software analysis techniques. A test compound which increases the fluorescence by at least 15% relative to fluorescence in the absence of a test compound is identified as a
10 compound which mobilizes intracellular calcium.

EXAMPLE 6

Effect of a test compound on phosphoinositide metabolism

15

- Cells which stably express human HM74-like GPCR cDNA are plated in 96-well plates and grown to confluence. The day before the assay, the growth medium is changed to 100 μ l of medium containing 1% serum and 0.5 μ Ci 3 H-myo-inositol. The plates are incubated overnight in a CO₂ incubator (5% CO₂ at 37°C). Immediately
20 before the assay, the medium is removed and replaced by 200 μ l of PBS containing 10 mM LiCl, and the cells are equilibrated with the new medium for 20 minutes. During this interval, cells also are equilibrated with antagonist, added as a 10 μ l aliquot of a 20-fold concentrated solution in PBS.

- 25 The 3 H-inositol phosphate accumulation from inositol phospholipid metabolism is started by adding 10 μ l of a solution containing a test compound. To the first well 10 μ l are added to measure basal accumulation. Eleven different concentrations of test compound are assayed in the following 11 wells of each plate row. All assays are performed in duplicate by repeating the same additions in two consecutive plate
30 rows.

The plates are incubated in a CO₂ incubator for one hour. The reaction is terminated by adding 15 µl of 50% v/v trichloroacetic acid (TCA), followed by a 40 minute incubation at 4°C. After neutralizing TCA with 40 µl of 1 M Tris, the content of the wells is transferred to a Multiscreen HV filter plate (Millipore) containing Dowex AG1-X8 (200-400 mesh, formate form). The filter plates are prepared by adding 200 µl of Dowex AG1-X8 suspension (50% v/v, water:resin) to each well. The filter plates are placed on a vacuum manifold to wash or elute the resin bed. Each well is washed 2 times with 200 µl of water, followed by 2 x 200 µl of 5 mM sodium tetraborate/60 mM ammonium formate.

10

The ³H-IPs are eluted into empty 96-well plates with 200 µl of 1.2 M ammonium formate/0.1 formic acid. The content of the wells is added to 3 ml of scintillation cocktail, and radioactivity is determined by liquid scintillation counting.

15

EXAMPLE 7

Receptor Binding Methods

Standard Binding Assays. Binding assays are carried out in a binding buffer containing 50 mM HEPES, pH 7.4, 0.5% BSA, and 5 mM MgCl₂. The standard assay for radioligand (*e.g.*, ¹²⁵I- test compound) binding to membrane fragments comprising HM74- like GPCR polypeptides is carried out as follows in 96 well microtiter plates (*e.g.*, Dynatech Immulon II Removawell plates). Radioligand is diluted in binding buffer+ PMSF/Baci to the desired cpm per 50 µl, then 50 µl aliquots are added to the wells. For non-specific binding samples, 5 µl of 40 µM cold ligand also is added per well. Binding is initiated by adding 150 µl per well of membrane diluted to the desired concentration (10-30 µg membrane protein/well) in binding buffer+ PMSF/Baci. Plates are then covered with Linbro mylar plate sealers (Flow Labs) and placed on a Dynatech Microshaker II. Binding is allowed to proceed at room temperature for 1-2 hours and is stopped by centrifuging the plate for 15 minutes at 2,000 x g. The supernatants are decanted, and the membrane

pellets are washed once by addition of 200 μ l of ice cold binding buffer, brief shaking, and recentrifugation. The individual wells are placed in 12 x 75 mm tubes and counted in an LKB Gammamaster counter (78% efficiency). Specific binding by this method is identical to that measured when free ligand is removed by rapid (3-5
5 seconds) filtration and washing on polyethyleneimine-coated glass fiber filters.

Three variations of the standard binding assay are also used.

1. Competitive radioligand binding assays with a concentration range of cold
10 ligand vs. 125 I-labeled ligand are carried out as described above with one modification. All dilutions of ligands being assayed are made in 40X PMSF/Baci to a concentration 40X the final concentration in the assay. Samples of peptide (5 μ l each) are then added per microtiter well. Membranes and radioligand are diluted in binding buffer without protease
15 inhibitors. Radioligand is added and mixed with cold ligand, and then binding is initiated by addition of membranes.
2. Chemical cross-linking of radioligand with receptor is done after a binding
20 step identical to the standard assay. However, the wash step is done with binding buffer minus BSA to reduce the possibility of non-specific cross-linking of radioligand with BSA. The cross-linking step is carried out as described below.
3. Larger scale binding assays to obtain membrane pellets for studies on
25 solubilization of receptor:ligand complex and for receptor purification are also carried out. These are identical to the standard assays except that (a) binding is carried out in polypropylene tubes in volumes from 1-250 ml, (b) concentration of membrane protein is always 0.5 mg/ml, and (c) for receptor purification, BSA concentration in the binding buffer is reduced to 0.25%,
30 and the wash step is done with binding buffer without BSA, which reduces BSA contamination of the purified receptor.

EXAMPLE 8

Chemical Cross-Linking of Radioligand to Receptor

5 After a radioligand binding step as described above, membrane pellets are resuspended in 200 μ l per microtiter plate well of ice-cold binding buffer without BSA. Then 5 μ l per well of 4 mM N-5-azido-2-nitrobenzoyloxysuccinimide (ANB-NOS, Pierce) in DMSO is added and mixed. The samples are held on ice and UV-irradiated for 10 minutes with a Mineralight R-52G lamp (UVP Inc., San Gabriel,
10 Calif.) at a distance of 5-10 cm. Then the samples are transferred to Eppendorf microfuge tubes, the membranes pelleted by centrifugation, supernatants removed, and membranes solubilized in Laemmli SDS sample buffer for polyacrylamide gel electrophoresis (PAGE). PAGE is carried out as described below. Radiolabeled proteins are visualized by autoradiography of the dried gels with Kodak XAR film
15 and DuPont image intensifier screens.

EXAMPLE 9

Membrane Solubilization

20 Membrane solubilization is carried out in buffer containing 25 mM Tris , pH 8, 10% glycerol (w/v) and 0.2 mM CaCl_2 (solubilization buffer). The highly soluble detergents including Triton X-100, deoxycholate, deoxycholate:lysolecithin, CHAPS, and zwittergent are made up in solubilization buffer at 10% concentrations and stored
25 as frozen aliquots. Lysolecithin is made up fresh because of insolubility upon freeze-thawing and digitonin is made fresh at lower concentrations due to its more limited solubility.

To solubilize membranes, washed pellets after the binding step are resuspended free
30 of visible particles by pipetting and vortexing in solubilization buffer at 100,000 x g

for 30 minutes. The supernatants are removed and held on ice and the pellets are discarded.

EXAMPLE 10

5

Assay of Solubilized Receptors

After binding of ^{125}I ligands and solubilization of the membranes with detergent, the intact R:L complex can be assayed by four different methods. All are carried out on ice or in a cold room at 4-10°C.).

10

1. Column chromatography (Knuhtsen *et al.*, *Biochem. J.* 254, 641-647, 1988). Sephadex G-50 columns (8 x 250 mm) are equilibrated with solubilization buffer containing detergent at the concentration used to solubilize membranes and 1 mg/ml bovine serum albumin. Samples of solubilized membranes (0.2-0.5 ml) are applied to the columns and eluted at a flow rate of about 0.7 ml/minute. Samples (0.18 ml) are collected. Radioactivity is determined in a gamma counter. Void volumes of the columns are determined by the elution volume of blue dextran. Radioactivity eluting in the void volume is considered bound to protein. Radioactivity eluting later, at the same volume as free ^{125}I ligands, is considered non-bound.
2. Polyethyleneglycol precipitation (Cuatrecasas, *Proc. Natl. Acad. Sci. USA* 69, 318-322, 1972). For a 100 μl sample of solubilized membranes in a 12 x 75 mm polypropylene tube, 0.5 ml of 1% (w/v) bovine gamma globulin (Sigma) in 0.1 M sodium phosphate buffer is added, followed by 0.5 ml of 25% (w/v) polyethyleneglycol (Sigma) and mixing. The mixture is held on ice for 15 minutes. Then 3 ml of 0.1 M sodium phosphate, pH 7.4, is added per sample. The samples are rapidly (1-3 seconds) filtered over Whatman GF/B glass fiber filters and washed with 4 ml of the phosphate buffer. PEG-precipitated receptor : ^{125}I -ligand complex is determined by gamma counting of the filters.

15

20

25

30

3. GFB/PEI filter binding (Bruns *et al.*, *Analytical Biochem.* 132, 74-81, 1983). Whatman GF/B glass fiber filters are soaked in 0.3% polyethyleneimine (PEI, Sigma) for 3 hours. Samples of solubilized membranes (25-100 μ l) are replaced in 12 x 75 mm polypropylene tubes. Then 4 ml of solubilization buffer without detergent is added per sample and the samples are immediately filtered through the GFB/PEI filters (1-3 seconds) and washed with 4 ml of solubilization buffer. CPM of receptor : 125 I-ligand complex adsorbed to filters are determined by gamma counting.
4. Charcoal/Dextran (Paul and Said, *Peptides* 7[Suppl. 1],147-149, 1986). Dextran T70 (0.5 g, Pharmacia) is dissolved in 1 liter of water, then 5 g of activated charcoal (Norit A, alkaline; Fisher Scientific) is added. The suspension is stirred for 10 minutes at room temperature and then stored at 4°C. until use. To measure R:L complex, 4 parts by volume of charcoal/dextran suspension are added to 1 part by volume of solubilized membrane. The samples are mixed and held on ice for 2 minutes and then centrifuged for 2 minutes at 11,000 x g in a Beckman microfuge. Free radioligand is adsorbed charcoal/dextran and is discarded with the pellet. Receptor : 125 I-ligand complexes remain in the supernatant and are determined by gamma counting.

EXAMPLE 11

25 *Receptor Purification*

Binding of biotinyl-receptor to GH₄ C1 membranes is carried out as described above. Incubations are for 1 hour at room temperature. In the standard purification protocol, the binding incubations contain 10 nM Bio-S29. 125 I ligand is added as a tracer at levels of 5,000-100,000 cpm per mg of membrane protein. Control incubations contain 10 μ M cold ligand to saturate the receptor with non-biotinylated ligand.

Solubilization of receptor:ligand complex also is carried out as described above, with 0.15% deoxycholate:lysolecithin in solubilization buffer containing 0.2 mM MgCl_2 , to obtain 100,000 x g supernatants containing solubilized R:L complex.

5 Immobilized streptavidin (streptavidin cross-linked to 6% beaded agarose, Pierce Chemical Co.; "SA-agarose") is washed in solubilization buffer and added to the solubilized membranes as 1/30 of the final volume. This mixture is incubated with constant stirring by end-over-end rotation for 4-5 hours at 4-10°C. Then the mixture is applied to a column and the non-bound material is washed through. Binding of
10 radioligand to SA-agarose is determined by comparing cpm in the 100,000 x g supernatant with that in the column effluent after adsorption to SA-agarose. Finally, the column is washed with 12-15 column volumes of solubilization buffer+0.15% deoxycholate:lysolecithin +1/500 (vol/vol) 100 x 4pase.

15 The streptavidin column is eluted with solubilization buffer+0.1 mM EDTA+0.1 mM EGTA+0.1 mM GTP-gamma-S (Sigma)+0.15% (wt/vol) deoxycholate:lysolecithin +1/1000 (vol/vol) 100.times.4pase. First, one column volume of elution buffer is passed through the column and flow is stopped for 20-30 minutes. Then 3-4 more column volumes of elution buffer are passed through. All the eluates are pooled.

20 Eluates from the streptavidin column are incubated overnight (12-15 hours) with immobilized wheat germ agglutinin (WGA agarose, Vector Labs) to adsorb the receptor via interaction of covalently bound carbohydrate with the WGA lectin. The ratio (vol/vol) of WGA-agarose to streptavidin column eluate is generally 1:400. A
25 range from 1:1000 to 1:200 also can be used. After the binding step, the resin is pelleted by centrifugation, the supernatant is removed and saved, and the resin is washed 3 times (about 2 minutes each) in buffer containing 50 mM HEPES, pH 8, 5 mM MgCl_2 , and 0.15% deoxycholate:lysolecithin. To elute the WGA-bound receptor, the resin is extracted three times by repeated mixing (vortex mixer on low
30 speed) over a 15-30 minute period on ice, with 3 resin columns each time, of 10 mM N-N'-N''-triacetylchitotriose in the same HEPES buffer used to wash the resin. After

each elution step, the resin is centrifuged down and the supernatant is carefully removed, free of WGA-agarose pellets. The three, pooled eluates contain the final, purified receptor. The material non-bound to WGA contain G protein subunits specifically eluted from the streptavidin column, as well as non-specific contaminants. All these fractions are stored frozen at -90°C.

EXAMPLE 12

Identification of test compounds that bind to HM74-like GPCR polypeptides

10

Purified HM74-like GPCR polypeptides comprising a glutathione-S-transferase protein and absorbed onto glutathione-derivatized wells of 96-well microtiter plates are contacted with test compounds from a small molecule library at pH 7.0 in a physiological buffer solution. HM74-like GPCR polypeptides comprise an amino acid sequence shown in SEQ ID NO. 2. The test compounds comprise a fluorescent tag. The samples are incubated for 5 minutes to one hour. Control samples are incubated in the absence of a test compound.

15

The buffer solution containing the test compounds is washed from the wells. Binding of a test compound to an HM74-like GPCR polypeptide is detected by fluorescence measurements of the contents of the wells. A test compound which increases the fluorescence in a well by at least 15% relative to fluorescence of a well in which a test compound was not incubated is identified as a compound which binds to an HM74-like GPCR polypeptide.

20

25

EXAMPLE 13

Identification of a test compound which decreases HM74-like GPCR gene expression

30

A test compound is administered to a culture of human gastric cells and incubated at 37°C for 10 to 45 minutes. A culture of the same type of cells incubated for the same time without the test compound provides a negative control.

RNA is isolated from the two cultures as described in Chirgwin *et al.*, *Biochem. 18*, 5294-99, 1979). Northern blots are prepared using 20 to 30 µg total RNA and hybridized with a ³²P-labeled HM74-like GPCR-specific probe at 65°C in Express-hyb (CLONTECH). The probe comprises at least 11 contiguous nucleotides selected from the complement of SEQ ID NO. 1. A test compound which decreases the HM74-like GPCR-specific signal relative to the signal obtained in the absence of the test compound is identified as an inhibitor of HM74-like GPCR gene expression.

10 EXAMPLE 14

Treatment of asthma with a reagent which specifically binds to an HM74-like GPCR gene product

15 Synthesis of antisense HM74-like GPCR oligonucleotides comprising at least 11 contiguous nucleotides selected from the complement of SEQ ID NO. 1 is performed on a Pharmacia Gene Assembler series synthesizer using the phosphoramidite procedure (Uhlmann *et al.*, *Chem. Rev. 90*, 534-83, 1990). Following assembly and deprotection, oligonucleotides are ethanol-precipitated twice, dried, and suspended in
20 phosphate-buffered saline (PBS) at the desired concentration. Purity of these oligonucleotides is tested by capillary gel electrophoreses and ion exchange HPLC. Endotoxin levels in the oligonucleotide preparation are determined using the Luminous Amebocyte Assay (Bang, *Biol. Bull. (Woods Hole, Mass.) 105*, 361-362, 1953).

25

The antisense oligonucleotides are administered intrabronchially to a patient with asthma. The severity of the patient's asthma is decreased.

EXAMPLE 15*Expression of HM74-like GPCR in human tissue*

5 A 339 base pair fragment of the HM74-like GPCR gene was amplified by standard PCR methods, well known to persons skilled in the art. The fragment was used to hybridize a Multiple Tissue Expression Array (MTEA, Clontech, Mountain View, CA, catalogue# 7775-1). Any other method to quantify the expression of the gene could be used as well. The same primers as used for the amplification of the 339 base
10 pair fragment were used for a reverse transcriptase (RT-)PCR with various human tissues and the transcripts were quantified. Methods to apply reverse transcriptase PCR for quantification of the transcription level of a gene are also well known to persons skilled in the art. The results are given in Table 1. High and very high expression was found in human fetal liver, liver, kidney and fetal thymus.

15

Table 1: Expression of HM74-like GPCR in various human tissues quantified by Multiple Tissue Expression Array (MTEA) and reverse transcript (RT-)PCR. Expression levels: -, not detected; (+), low; +, medium; ++, high; +++, very high).

- 77 -

Tissue Type	MTEA	RT-PCR
brain	-	-
testis	-	(+)
pancreas	(+)	(+)
stomach	(+)	+
cerebellum	(+)	(+)
tracheae	(+)	+
adrenal gland	(+)	+
skeletal muscle	-	(+)
salivary gland	-	(+)
small intestine	(+)	+
prostata	(+)	+
fetal liver	(+)	++
placenta	(+)	(+)
fetal brain	-	(+)
uterus	(+)	(+)
mammary gland	-	-
heart	-	-
spleen	-	-
lung	-	-
HeLa cells	-	-
liver	++	+++
kidney	++	+++
thymus	++ (fetal)	(+)
bone marrow	(+)	+
thyroid	-	-
colon	-	+
bladder	(+)	+
spinal cord	-	(+)
peripheral blood	-	-

CLAIMS

1. An isolated polynucleotide encoding a HM74-like GPCR polypeptide and
5 being selected from the group consisting of:
- a) a polynucleotide encoding a HM74-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:
- 10 amino acid sequences which are at least about 50% identical to
the amino acid sequence shown in SEQ ID NO. 2;
the amino acid sequence shown in SEQ ID NO. 2;
amino acid sequences which are at least about 50% identical to
the amino acid sequence shown in SEQ ID NO. 5;
15 the amino acid sequence shown in SEQ ID NO. 5;
amino acid sequences which are at least about 50% identical to
the amino acid sequence shown in SEQ ID NO. 6;
the amino acid sequence shown in SEQ ID NO. 6;
amino acid sequences which are at least about 50% identical to
20 the amino acid sequence shown in SEQ ID NO. 7; and
the amino acid sequence shown in SEQ ID NO. 7.
- b) a polynucleotide comprising the sequence of SEQ ID NOS: 1 or 3;
- 25 c) a polynucleotide which hybridizes under stringent conditions to a
polynucleotide specified in (a) and (b);
- d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of
30 the genetic code; and

- e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a to (d).
2. An expression vector containing any polynucleotide of claim 1.
- 5 3. A host cell containing the expression vector of claim 2.
4. A substantially purified HM74-like GPCR polypeptide encoded by a polynucleotide of claim 1.
- 10 5. A method for producing a HM74-like GPCR polypeptide, wherein the method comprises the following steps:
- 15 a) culturing the host cell of claim 3 under conditions suitable for the expression of the HM74-like GPCR polypeptide; and
- b) recovering the HM74-like GPCR polypeptide from the host cell culture.
- 20 6. A method for detection of a polynucleotide encoding a HM74-like GPCR polypeptide in a biological sample comprising the following steps:
- a) hybridizing any polynucleotide of claim 1 to a nucleic acid material of a biological sample, thereby forming a hybridization complex; and
- b) detecting said hybridization complex.
- 25 7. The method of claim 6, wherein before hybridization, the nucleic acid material of the biological sample is amplified.
8. A method for the detection of a polynucleotide of claim 1 or a HM74-like GPCR polypeptide of claim 4 comprising the steps of:
- 30

contacting a biological sample with a reagent which specifically interacts with the polynucleotide or the HM74-like GPCR polypeptide.

- 5 9. A diagnostic kit for conducting the method of any one of claims 6 to 8.
10. A method of screening for agents which decrease the activity of a HM74-like GPCR, comprising the steps of:
- 10 contacting a test compound with any HM74-like GPCR polypeptide encoded by any polynucleotide of claim 1;
- detecting binding of the test compound to the HM74-like GPCR polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential therapeutic agent for decreasing the activity of a HM74-like GPCR.
- 15 11. A method of screening for agents which regulate the activity of a HM74-like GPCR, comprising the steps of:
- contacting a test compound with a HM74-like GPCR polypeptide encoded by
- 20 any polynucleotide of claim 1; and
- detecting a HM74-like GPCR activity of the polypeptide, wherein a test compound which increases the HM74-like GPCR activity is identified as a potential therapeutic agent for increasing the activity of the HM74-like GPCR, and wherein a test compound which decreases the HM74-like GPCR
- 25 activity of the polypeptide is identified as a potential therapeutic agent for decreasing the activity of the HM74-like GPCR.
- 30 12. A method of screening for agents which decrease the activity of a HM74-like GPCR, comprising the steps of:

- 5 contacting a test compound with any polynucleotide of claim 1 and detecting binding of the test compound to the polynucleotide, wherein a test compound which binds to the polynucleotide is identified as a potential therapeutic agent for decreasing the activity of HM74-like GPCR.
13. A method of reducing the activity of HM74-like GPCR, comprising the steps of:
- 10 contacting a cell with a reagent which specifically binds to any polynucleotide of claim 1 or any HM74-like GPCR polypeptide of claim 4, whereby the activity of HM74-like GPCR is reduced.
14. A reagent that modulates the activity of a HM74-like GPCR polypeptide or a
15 polynucleotide wherein said reagent is identified by the method of any of the claim 10 to 12.
15. A pharmaceutical composition, comprising:
- 20 the expression vector of claim 2 or the reagent of claim 14 and a pharmaceutically acceptable carrier.
16. Use of the pharmaceutical composition of claim 15 for modulating the activity of a HM74-like GPCR in a disease.
- 25 17. Use of claim 16 wherein the disease is bacterial, fungal, protozoan and viral infection, pain, cancer, anorexia, bulimia, asthma, CNS disease, cardiovascular disease, hypotension, hypertension, angina pectoris, myocardial infarction, urinary retention, osteoporosis, obesity, ulcer, asthma,
30 inflammation, allergy, multiple sclerosis, benign prostatic hypertrophy, psychotic and neurological disorder and dyskinesias.

18. A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7.
- 5 19. The cDNA of claim 18 which comprises SEQ ID NO. 1 or 3.
20. The cDNA of claim 18 which consists of SEQ ID NO. 1 or 3.
- 10 21. An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7.
22. The expression vector of claim 21 wherein the polynucleotide consists of SEQ ID NO. 1 or 3.
- 15 23. A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7.
- 20 24. The host cell of claim 23 wherein the polynucleotide consists of SEQ ID NO. 1 or 3.
- 25 25. A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7.
26. The purified polypeptide of claim 25 which consists of the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7.
27. A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7.

28. A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7, comprising the steps of:
- 5 culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed; and isolating the polypeptide.
29. The method of claim 28 wherein the expression vector comprises SEQ ID NO. 1 or 3.
- 10 30. A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7, comprising the steps of:
- 15 hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO. 1 or 3 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and
- 20 detecting the hybridization complex.
31. The method of claim 30 further comprising the step of amplifying the nucleic acid material before the step of hybridizing.
- 25 32. A kit for detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7, comprising:
- a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO. 1 or 3; and
- 30 instructions for the method of claim 30.

33. A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7, comprising the steps of:
- 5 contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex; and detecting the reagent-polypeptide complex.
34. The method of claim 33 wherein the reagent is an antibody.
- 10 35. A kit for detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7, comprising:
- an antibody which specifically binds to the polypeptide; and
- 15 instructions for the method of claim 33.
36. A method of screening for agents which can modulate the activity of a human HM74-like GPCR, comprising the steps of:
- 20 contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of: (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7 and (2) the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7; and
- 25 detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the human HM74-like GPCR.
- 30 37. The method of claim 36 wherein the step of contacting is in a cell.

38. The method of claim 36 wherein the cell is *in vitro*.
39. The method of claim 36 wherein the step of contacting is in a cell-free system.
- 5 40. The method of claim 36 wherein the polypeptide comprises a detectable label.
41. The method of claim 36 wherein the test compound comprises a detectable label.
- 10 42. The method of claim 36 wherein the test compound displaces a labeled ligand which is bound to the polypeptide.
43. The method of claim 36 wherein the polypeptide is bound to a solid support.
- 15 44. The method of claim 36 wherein the test compound is bound to a solid support.
- 20 45. A method of screening for agents which modulate an activity of a human HM74-like GPCR, comprising the steps of:
- 25 contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of: (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7 and (2) the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7; and
- 30 detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human HM74-like GPCR, and wherein a test

compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human HM74-like GPCR.

5

46. The method of claim 45 wherein the step of contacting is in a cell.

47. The method of claim 45 wherein the cell is *in vitro*.

48. The method of claim 45 wherein the step of contacting is in a cell-free system.

10

49. The method of claim 45 wherein the activity is cyclic AMP formation.

50. The method of claim 45 wherein the activity is mobilization of intracellular calcium.

15

51. The method of claim 45 wherein the activity is phosphoinositide metabolism.

52. A method of screening for agents which modulate an activity of a human HM74-like GPCR, comprising the steps of:

20

contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO. 1 or 3; and

25

detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human HM74-like GPCR.

53. The method of claim 52 wherein the product is a polypeptide.

30

54. The method of claim 52 wherein the product is RNA.

55. A method of reducing activity of a human HM74-like GPCR, comprising the step of:
- 5 contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO. 1 or 3, whereby the activity of a human HM74-like GPCR is reduced.
56. The method of claim 55 wherein the product is a polypeptide.
- 10 57. The method of claim 56 wherein the reagent is an antibody.
58. The method of claim 55 wherein the product is RNA.
59. The method of claim 58 wherein the reagent is an antisense oligonucleotide.
- 15 60. The method of claim 59 wherein the reagent is a ribozyme.
61. The method of claim 55 wherein the cell is *in vitro*.
- 20 62. The method of claim 55 wherein the cell is *in vivo*.
63. A pharmaceutical composition, comprising:
- 25 a reagent which specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7; and
- a pharmaceutically acceptable carrier.
64. The pharmaceutical composition of claim 63 wherein the reagent is an antibody.
- 30

65. A pharmaceutical composition, comprising:

a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO. 1 or 3; and

5

a pharmaceutically acceptable carrier.

66. The pharmaceutical composition of claim 65 wherein the reagent is a ribozyme.

10

67. The pharmaceutical composition of claim 65 wherein the reagent is an antisense oligonucleotide.

68. The pharmaceutical composition of claim 65 wherein the reagent is an antibody.

15

69. A pharmaceutical composition, comprising:

an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, 5, 6 and 7; and

20

a pharmaceutically acceptable carrier.

70. The pharmaceutical composition of claim 69 wherein the expression vector comprises SEQ ID NO. 1 or 3.

25

71. A method of treating a HM74-like GPCR disease, comprising the step of:

administering to a patient in need thereof a therapeutically effective dose of a reagent that modulates a function of a human HM74-like GPCR, whereby symptoms of the HM74-like GPCR disease are ameliorated.

30

72. The method of claim 71 wherein the reagent is identified by the method of claim 36.
- 5 73. The method of claim 71 wherein the reagent is identified by the method of claim 45.
74. The method of claim 71 wherein the reagent is identified by the method of claim 52.
- 10 75. The method of claim 71 wherein the disease bacterial, fungal, protozoan and viral infection, pain, cancer, anorexia, bulimia, asthma, CNS disease, cardiovascular disease, hypotension, hypertension, angina pectoris, myocardial infarction, urinary retention, osteoporosis, obesity, ulcer, asthma, inflammation, allergy, multiple sclerosis, benign prostatic hypertrophy, 15 psychotic and neurological disorder and dyskinesias.

Fig. 1

AGGGAGGGCTGCAGGGTCCCCCTTGGCCTGCAAACAGGAACACAGGGTGTTTCTCAGTGG
CTGCGAGAATGCTGATGAAAACCCAGGATGTTGTGTACCGTGGTGGCCAGCTGATAGT
GCCAATCATCCCACCTTTGCCCTGAGCACTCCTGCAGGGGTAGAAGACTCCAGAACCTTCT
CTCAGGCCCATGGCCCAAGCAGCCCATGGAACCTTCATAACCTGAGCTCTCCATCTCCCTC
TCTCTCCTCCTCTGTTCTCCCTCCCTCCTTCTCTCCCTCACCTCCTCTGCTCCCTCTGC
CTTTACCACTGTGGGGGGGTCCCTCTGGAGGGCCCTGCCACCCACCTCTTCCTCGCTGGT
GTCTGCCTTCCTGGCACCAATCCTGGCCCTGGAGTTTGTCTGCGCCCTGGTGGGGAACAG
TTTGGCCCTCTTCATCTTCTGCATCCACACGCGGCCCTGGACCTCCAACACGGTGTTCT
GGTCAGCCTGGTGGCCGCTGACTTCCTCCTGATCAGCAACCTGCCCCCTCCGCGTGGACTA
CTACCTCCTCCATGAGACCTGGCGCTTTGGGGCTGCTGCCTGCAAAGTCAACCTCTTCAT
GCTGTCCACCAACCGCACGGCCAGCGTTGTCTTCCTCACAGCCATCGCACTCAACCGCTA
CCTGAAGGTGGTGCAGCCCCACCACGTGCTGAGCCGTGCTTCCGTGGGGGCAGCTGCCCCG
GGTGGCCGGGGGACTCTGGGTGGGCATCCTGCTCCTCAACGGGCACCTGCTCCTGAGCAC
CTTCTCCGGCCCCCTCCTGCCTCAGCTACAGGGTGGGCACGAAGCCCTCGGCCTCGCTCCG
CTGGCACCAAGGCACTGTACCTGCTGGAGTTCTTCCTGCCACTGGCGCTCATCCTCTTTGC
TATTGTGAGCATTGGGCTCACCATCCGGAACCGTGGTCTGGGCGGGCAGGCAGGCCCCGA
GAGGGCCATGCGTGTGCTGGCCATGGTGGTGGCCGTCTACACCATCTGCTTCTTGCCCAG
CATCATCTTTGGCATGGCTTCCATGGTGGCTTTCTGGCTGTCCGCCTGCCGATCCCTGGA
CCTCTGCACACAGCTCTTCCATGGCTCCCTGGCCTTCACCTACCTCAACAGTGTCTTGGA
CCCCGTGCTCTACTGCTTCTCTAGCCCCAACTTCCTCCACCAGAGCCGGGCCTTGCTGGG
CCTCACGCGGGGGCCGGCAGGGCCCAGTGAGCGACGAGAGCTCCTACCAACCTCCAGGCA
GTGGCGCTACCGGGAGGCCTCTAGGAAGGCGGAGGCCATAGGGAAGCTGAAAGTGCAGGG
CGAGGTCTCTCTGGAAAAGGAAGGCTCCTCCAGGGCTGAGGGCCAGCTGCAGGGCTGCA
GCGCTGTGGGGGTAAAGGGCTGCCGCGCTCTGGCCTGGAGGGACAAGGCCAGCACACGGTG
CCTCAACCA

Fig. 2

MLCHRRGGQLI	VPIIPLCPEH	SCRGRRLQNL	LSGPWPKQPM	ELHNLSSPSP
SLSSSVLPSP				
FSPSPSSAPS	AFTTVGGSSG	GPCHPTSSSL	VSAFLAPILA	LEFVLGLVGN
SLALFIFCIH				
TRPWTSTNTVF	LVSLVAADFL	LISNLPLRVD	YLLHETWRF	GAAACKVNLF
MLSTNRTASV				
VFLTALALNR	YLKVVQPHHV	LSRASVGAAA	RVAGGLWVGI	LLLNHLLLS
TFSGPSCLSY				
RVGTKPSASL	RWHQALYLLE	FFLPLALILF	AIVSIGLTIR	NRGLGGQAGP
QRAMRVLAMV				
VAVYTICFLP	SIIFGMASMV	AFWLSACRSL	DLCTQLFHGS	LAFTYLNSVL
DPVLYCFSSP				
NFLHQSRALL	GLTRGRQGPV	SDESSYQPSR	QWRYREASRK	AEAIGKLKVQ
GEVSLEKEGS				
SQG				

Fig. 3

ATGTTGTGTCACCGTGGTGGCCAGCTGATAGT
GCCAATCATCCCACCTTTGCCCTGAGCACTCCTGCAGGGGTAGAAGACTCCAGAACCTTCT
CTCAGGCCCATGGCCCAAGCAGCCCATGGAACTTCATAACCTGAGCTCTCCATCTCCCTC
TCTCTCCTCCTCTGTTCTCCCTCCCTCCTTCTCTCCCTCACCTCCTCTGCTCCCTCTGC
CTTTACCACTGTGGGGGGGTCTCTGGAGGGCCCTGCCACCCACCTCTTCCTCGCTGGT
GTCTGCCTTCCTGGCACCAATCCTGGCCCTGGAGTTTGTCTCTGGGCCTGGTGGGGAACAG
TTTGGCCCTCTTCATCTTCTGCATCCACACGCGGCCCTGGACCTCCAACACGGTGTTCT
GGTCAGCCTGGTGGCCGCTGACTTCCTCCTGATCAGCAACCTGCCCCCTCCGCGTGGACTA
CTACCTCCTCCATGAGACCTGGCGCTTTGGGGCTGCTGCCTGCAAAGTCAACCTCTTCAT
GCTGTCCACCAACCGCACGGCCAGCGTTGTCTTCCTCACAGCCATCGCACTCAACCGCTA
CCTGAAGGTGGTGCAGCCCCACCACGTGCTGAGCCGTGCTTCCGTGGGGGCAGCTGCCCCG
GGTGGCCGGGGGACTCTGGGTGGGCATCCTGCTCCTCAACGGGCACCTGCTCCTGAGCAC
CTTCTCCGGCCCCCTCCTGCCTCAGCTACAGGGTGGGCACGAAGCCCTCGGCCTCGCTCCG
CTGGCACCAAGGCACTGTACCTGCTGGAGTTCTTCCTGCCACTGGCGCTCATCCTCTTTGC
TATTGTGAGCATTGGGCTCACCATCCGGAACCGTGGTCTGGGCGGGCAGGCAGGCCCCGCA
GAGGGCCATGCGTGTGCTGGCCATGGTGGTGGCCGTCTACACCATCTGCTTCTTGCCCAG
CATCATCTTTGGCATGGCTTCCATGGTGGCTTTCTGGCTGTCCGCTGCCGATCCCTGGA
CCTCTGCACACAGCTCTTCCATGGCTCCCTGGCCTTCACCTACCTCAACAGTGTCTGGA
CCCCGTGCTCTACTGCTTCTCTAGCCCCAACTTCCTCCACCAGAGCCGGGCCTTGCTGGG
CCTCACGCGGGGCCGGCAGGGCCCAGTGAGCGACGAGAGCTCCTACCAACCCTCCAGGCA
GTGGCGCTACCGGGAGGCCTCTAGGAAGGCGGAGGCCATAGGGAAGCTGAAAGTGCAGGG
CGAGGTCTCTCTGGAAAAGGAAGGCTCCTCCCAGGGCTGA

Fig. 4

MNRHHLQDHF	LEIDKKNCCV	FRDDFIKVL	PPVLGLEFIF	GLLGNGLALW
IFCFHLKSWK				
SSRIFLFNLA	VADFLLIICL	PFVMDYYVRR	SDWNFGDIPC	RLVLFMFAMN
RQGSIIFLTIV				
VAVDYFRV	HPHHALNKIS	NWTAAIISCL	LWGITVGLTV	HLLKKKLLIQ
NGPANVCISF				
SICHTFRWHE	AMFLLEFLLP	LGIILFCSAR	IIWSLRQRQM	DRHAKIKRAI
TFIMVVAIVF				
VICFLPSVVV	RIRIFWLLHT	SGTQNCVYR	SVDLAFFITL	SFTYMNSMLD
PVYYYFSSPS				
FPNFFSTLIN	RCLQRKMTGE	PDNNRSTSVE	LTGDPNKTRG	APEALMANS
EPWSPSYLGP				
TSNNHKKGH	CHQEPASLEK	QLGCCIE		

Fig. 5

WRFGAAACKVNLFMLSTNRTASVFLTAIALNRYLkVVQP

Fig. 6

NSVLDPVLYCFSSPNFL

Fig. 7

AGpQRAMRVLAMVVAVYTICFLPSIIF

Fig. 8

```
BLASTP - alignment of 33 TR against swiss|P49019|HM74 HUMAN
This hit is scoring at : 6e-57 (expectation value)

Alignment length (overlap) : 286

Identities : 42 %

Scoring matrix : BLOSUM62 (used to infer consensus pattern)

Database searched : nrdb

Q:  91 VXAF LAPILALEFVLGLVGNLALFIFCIHTRPWTSTNTVFLVSLVAADFLLISNLP LRV D
    :...L.P:L.LEF::GL:GN.LAL:IFC.H::W.S:::FL.:L..ADFLLI  LP.:D
H:  26 IAKVLP PVLGLEFIFGLLGNGLALWIFCFHLKSWKSSRIFLENLAVADFLLIICLPFVMD

    YLLHETWRFGAAACKVNLEMLSTNRTASVFLTAIALNRYLKVVQPHHVL SRASVGAAA
    YY: ...W.FG .C:: LFM.:.NR..S::FLT.:A::RY.:VV.PHH.L:::S .AA
    YVRRSDWNFGDIPCRLLVLFMFAMNRQGSIIFLTIVVAVDRYFRVVPHPHALNKISNWTAA

    RVAGGIWVGII.I.I.NGHI.I.--I.STFSGPS--CI.SYRVCTKPSAST,RWHOAI,YI.I.EFFT,PI.
```

Fig. 9

BLOCK search results:			
AC#	Description	Strength	Score
BL00237A	0 G-protein coupled receptors proteins.	1258	1232
AA#	157 WRFGAAACKVNLFMLSTNRTASVVFLTAIALNRYLKVVQP (SEQ ID NO:5)		
BL00237D	0 G-protein coupled receptors proteins.	1222	1199
AA#	346 NSVLDPVLYCFSSPNFL (SEQ ID NO:6)		

Fig. 10

MLCHRGGQLI	VPIIPLCPEH	SCRGRRLQNL	LSGPWPKQPM	ELHNLSSPSP
SLSSSVLPPS				
FSPSPSSAPS	AFTTVGGSSG	GPCHPTSSSL	VSAFLAPILA	LEFVLGLVGN
SLALFIFCIH				
TRPWTSENTVF	LVSLVAADFL	LISNLPLRVD	YLLHETWRF	GAAACKVNLF
MLSTNRTASV				
VFLTAIALNR	YLKVVQPHHV	LSRASVGAAA	RVAGGLWVGI	LLLNHLLLLS
TFSGPSCLSY				
RVGTPKSASL	RWHQALYLLE	FFLPLALILF	AIVSIGLTIR	NRGLGGQAGP
GRAMRVLAMV				
VAVYTICFLP	SIIFGMASMV	AFWLSACRSL	DLCTQLFHGS	LAFTYLNVL
DPVLYCFSSP				
NFLHQSRALL	GLTRGRQGPV	SDESSYQPSR	QWRYREASRK	AEAIGKLKVQ
GEVSLEKEGS				
SQG				

SEQUENCE LISTING

<110> Bayer AG

Bull, Christof

<120> REGULATION OF HUMAN HM74-LIKE G PROTEIN COUPLED RECEPTOR

<130> Lio 080 foreign countries

<150> 60/208,912

<151> 2000-06-05

<160> 8

<170> PatentIn version 3.0

<210> 1

<211> 1449

<212> DNA

<213> Homo sapiens

<400> 1
aggaggaggct gcagggttcc ccttggcctg caaacaggaa cacagggtgt ttctcagtgg 60
ctgcgagaat gctgatgaaa accccaggat gttgtgtcac cgtggtggcc agctgatagt 120
gccaatcatc ccactttgcc ctgagcactc ctgcaggggt agaagactcc agaaccctct 180
ctcaggccca tggcccaagc agcccatgga acttcataac ctgagctctc catctccctc 240
tctctectcc tctgttctcc ctccctcctt ctctccctca cctcctctg ctccctctgc 300
ctttaccact gtgggggggt cctctggagg gccctgccac cccacctctt cctcgtggt 360
gtctgccttc ctggcaccaa tcctggccct ggagtttgtc ctgggcctgg tggggaacag 420
tttgccctc ttcattctct gcattcacac gcggccctgg acctccaaca cgggtgttct 480
ggtcagcctg gtggccgctg acttcctcct gatcagcaac ctgcccctcc gcgtggacta 540
ctacctctc catgagacct ggcgctttgg ggctgctgcc tgcaaagtca acctcttcat 600

gctgtccacc aaccgcacgg ccagcgttgt cttcctcaca gccatcgcac tcaaccgcta 660
 cctgaagggtg gtgcagcccc accacgtgct gagccgtgct tccgtggggg cagctgcccg 720
 ggtggccggg ggactctggg tgggcatcct gctcctcaac gggcacctgc tcctgagcac 780
 cttctccggc ccctcctgcc tcagctacag ggtgggcacg aagccctcgg cctcgctccg 840
 ctggcaccag gcaactgtacc tgctggagtt cttcctgcca ctggcgctca tcctctttgc 900
 tattgtgagc attggggtca ccatccggaa ccgtgggtctg ggcgggcagg caggcccgc 960
 gagggccatg cgtgtgctgg ccatgggtgg ggcgtctac accatctgct tcttgcccag 1020
 catcatcttt ggcatggctt ccatgggtggc tttctggctg tccgcctgcc gatccctgga 1080
 cctctgcaca cagctcttcc atggctccct ggccttcacc tacctcaaca gtgtcctgga 1140
 ccccgctgctc tactgcttct ctagcccca cttcctccac cagagccggg ccttgctggg 1200
 cctcacgcgg ggccggcagg gccagtgag cgacgagagc tcctaccaac cctccaggca 1260
 gtggcgctac cgggaggcct ctaggaaggc ggaggccata ggggaagctga aagtgcaggg 1320
 cgaggtctct ctggaaaagg aaggctcctc ccagggtga gggccagctg cagggtgca 1380
 gcgctgtggg ggtaagggt gccgcgtctt ggcctggagg gacaaggcca gcacacggtg 1440
 cctcaacca 1449

<210> 2

<211> 423

<212> PRT

<213> Homo sapiens

<400> 2

Met Leu Cys His Arg Gly Gly Gln Leu Ile Val Pro Ile Ile Pro Leu
 1 5 10 15
 Cys Pro Glu His Ser Cys Arg Gly Arg Arg Leu Gln Asn Leu Leu Ser
 20 25 30
 Gly Pro Trp Pro Lys Gln Pro Met Glu Leu His Asn Leu Ser Ser Pro
 35 40 45
 Ser Pro Ser Leu Ser Ser Ser Val Leu Pro Pro Ser Phe Ser Pro Ser
 50 55 60
 Pro Ser Ser Ala Pro Ser Ala Phe Thr Thr Val Gly Gly Ser Ser Gly
 65 70 75 80
 Gly Pro Cys His Pro Thr Ser Ser Ser Leu Val Ser Ala Phe Leu Ala
 85 90 95

Pro Ile Leu Ala Leu Glu Phe Val Leu Gly Leu Val Gly Asn Ser Leu
 100 105 110
 Ala Leu Phe Ile Phe Cys Ile His Thr Arg Pro Trp Thr Ser Asn Thr
 115 120 125
 Val Phe Leu Val Ser Leu Val Ala Ala Asp Phe Leu Leu Ile Ser Asn
 130 135 140
 Leu Pro Leu Arg Val Asp Tyr Tyr Leu Leu His Glu Thr Trp Arg Phe
 145 150 155 160
 Gly Ala Ala Ala Cys Lys Val Asn Leu Phe Met Leu Ser Thr Asn Arg
 165 170 175
 Thr Ala Ser Val Val Phe Leu Thr Ala Ile Ala Leu Asn Arg Tyr Leu
 180 185 190
 Lys Val Val Gln Pro His His Val Leu Ser Arg Ala Ser Val Gly Ala
 195 200 205
 Ala Ala Arg Val Ala Gly Gly Leu Trp Val Gly Ile Leu Leu Leu Asn
 210 215 220
 Gly His Leu Leu Leu Ser Thr Phe Ser Gly Pro Ser Cys Leu Ser Tyr
 225 230 235 240
 Arg Val Gly Thr Lys Pro Ser Ala Ser Leu Arg Trp His Gln Ala Leu
 245 250 255
 Tyr Leu Leu Glu Phe Phe Leu Pro Leu Ala Leu Ile Leu Phe Ala Ile
 260 265 270
 Val Ser Ile Gly Leu Thr Ile Arg Asn Arg Gly Leu Gly Gly Gln Ala
 275 280 285
 Gly Pro Gln Arg Ala Met Arg Val Leu Ala Met Val Val Ala Val Tyr
 290 295 300
 Thr Ile Cys Phe Leu Pro Ser Ile Ile Phe Gly Met Ala Ser Met Val
 305 310 315 320
 Ala Phe Trp Leu Ser Ala Cys Arg Ser Leu Asp Leu Cys Thr Gln Leu
 325 330 335
 Phe His Gly Ser Leu Ala Phe Thr Tyr Leu Asn Ser Val Leu Asp Pro
 340 345 350
 Val Leu Tyr Cys Phe Ser Ser Pro Asn Phe Leu His Gln Ser Arg Ala
 355 360 365
 Leu Leu Gly Leu Thr Arg Gly Arg Gln Gly Pro Val Ser Asp Glu Ser
 370 375 380
 Ser Tyr Gln Pro Ser Arg Gln Trp Arg Tyr Arg Glu Ala Ser Arg Lys
 385 390 395 400
 Ala Glu Ala Ile Gly Lys Leu Lys Val Gln Gly Glu Val Ser Leu Glu
 405 410 415
 Lys Glu Gly Ser Ser Gln Gly
 420

<210> 3

<211> 1272

<212> DNA

<213> Homo sapiens

<400> 3

```

atgttggtg accgtggtgg ccagctgata gtgccaatca tcccactttg ccctgagcac      60
tcctgcaggg gtagaagact ccagaacctt ctctcaggcc catggcccaa gcagcccatg     120
gaacttcata acctgagctc tccatctccc tctctctcct cctctgttct cctccctcc      180
ttctctccct caccctctct tgctccctct gcctttacca ctgtgggggg gtcctctgga     240
gggccctgcc accccacctc ttctctgctg gtgtctgcct tcctggcacc aatcctggcc      300
ctggagtttg tcctgggcct ggtggggaac agtttgggcc tttcatctt ctgcatccac      360
acgcgccctt ggacctcaa caccgtgttc ctggtcagcc tgggtggcgc tgacttcctc      420
ctgatcagca acctgcccct ccgcgtggac tactacctcc tccatgagac ctggcgcttt      480
ggggctgctg cctgcaaagt caacctcttc atgctgtcca ccaaccgcac ggccagcggt      540
gtcttcctca cagccatcgc actcaaccgc tacctgaagg tgggtgcagc ccaccacgtg      600
ctgagccgtg cttccgtggg ggcagctgcc cgggtggccg ggggactctg ggtgggcatc      660
ctgctcctca acgggcacct gtcctgagc accttctccg gcccctcctg cctcagctac      720
agggtgggca cgaagccctc ggccctcgtc cgtggcacc aggcactgta cctgctggag      780
ttcttcctgc cactggcgct catcctcttt gctattgtga gcattgggct caccatccgg      840
aaccgtggtc tgggcgggca ggcaggcccg cagagggcca tgctgtgct ggccatgggtg      900
gtggcgtct acaccatctg cttcttgccc agcatcatct ttggcatggc ttccatgggtg      960
gctttctggc tgtccgctg ccgatccctg gacctctgca cacagctctt ccatggctcc     1020
ctggccttca cctacctcaa cagtgtcctg gaccccgctg tctactgctt ctctagcccc     1080
aacttcctcc accagagccg ggccctgctg ggccctcacgc ggggcgggca gggcccagtg     1140
agcgacgaga gtcctacca accctccagg cagtggcgct accgggaggc ctctaggaag     1200
gcggaggcca tagggaagct gaaagtgcag ggcgaggtct ctctggaaaa ggaaggctcc     1260
tcccagggt ga                                                                1272

```

<210> 4

<211> 387

<212> PRT

<213> Homo sapiens

<400> 4

```

Met Asn Arg His His Leu Gln Asp His Phe Leu Glu Ile Asp Lys Lys
1      5      10      15

Asn Cys Cys Val Phe Arg Asp Asp Phe Ile Ala Lys Val Leu Pro Pro
20      25      30

Val Leu Gly Leu Glu Phe Ile Phe Gly Leu Leu Gly Asn Gly Leu Ala
35      40      45

Leu Trp Ile Phe Cys Phe His Leu Lys Ser Trp Lys Ser Ser Arg Ile
50      55      60

Phe Leu Phe Asn Leu Ala Val Ala Asp Phe Leu Leu Ile Ile Cys Leu
65      70      75      80

Pro Phe Val Met Asp Tyr Tyr Val Arg Arg Ser Asp Trp Asn Phe Gly
85      90      95

Asp Ile Pro Cys Arg Leu Val Leu Phe Met Phe Ala Met Asn Arg Gln
100     105     110

Gly Ser Ile Ile Phe Leu Thr Val Val Ala Val Asp Arg Tyr Phe Arg
115     120     125

Val Val His Pro His His Ala Leu Asn Lys Ile Ser Asn Trp Thr Ala
130     135     140

Ala Ile Ile Ser Cys Leu Leu Trp Gly Ile Thr Val Gly Leu Thr Val
145     150     155     160

His Leu Leu Lys Lys Lys Leu Leu Ile Gln Asn Gly Pro Ala Asn Val
165     170     175

Cys Ile Ser Phe Ser Ile Cys His Thr Phe Arg Trp His Glu Ala Met
180     185     190

Phe Leu Leu Glu Phe Leu Leu Pro Leu Gly Ile Ile Leu Phe Cys Ser
195     200     205

Ala Arg Ile Ile Trp Ser Leu Arg Gln Arg Gln Met Asp Arg His Ala
210     215     220

Lys Ile Lys Arg Ala Ile Thr Phe Ile Met Val Val Ala Ile Val Phe
225     230     235     240

Val Ile Cys Phe Leu Pro Ser Val Val Val Arg Ile Arg Ile Phe Trp
245     250     255

Leu Leu His Thr Ser Gly Thr Gln Asn Cys Glu Val Tyr Arg Ser Val
260     265     270

Asp Leu Ala Phe Phe Ile Thr Leu Ser Phe Thr Tyr Met Asn Ser Met
275     280     285

```

Leu Asp Pro Val Val Tyr Tyr Phe Ser Ser Pro Ser Phe Pro Asn Phe
 290 295 300
 Phe Ser Thr Leu Ile Asn Arg Cys Leu Gln Arg Lys Met Thr Gly Glu
 305 310 315 320
 Pro Asp Asn Asn Arg Ser Thr Ser Val Glu Leu Thr Gly Asp Pro Asn
 325 330 335
 Lys Thr Arg Gly Ala Pro Glu Ala Leu Met Ala Asn Ser Gly Glu Pro
 340 345 350
 Trp Ser Pro Ser Tyr Leu Gly Pro Thr Ser Asn Asn His Ser Lys Lys
 355 360 365
 Gly His Cys His Gln Glu Pro Ala Ser Leu Glu Lys Gln Leu Gly Cys
 370 375 380
 Cys Ile Glu
 385

<210> 5

<211> 40

<212> PRT

<213> Homo sapiens

<400> 5

Trp Arg Phe Gly Ala Ala Ala Cys Lys Val Asn Leu Phe Met Leu Ser
 1 5 10 15
 Thr Asn Arg Thr Ala Ser Val Val Phe Leu Thr Ala Ile Ala Leu Asn
 20 25 30
 Arg Tyr Leu Lys Val Val Gln Pro
 35 40

<210> 6

<211> 17

<212> PRT

<213> Homo sapiens

<400> 6

Asn Ser Val Leu Asp Pro Val Leu Tyr Cys Phe Ser Ser Pro Asn Phe
 1 5 10 15
 Leu

<210> 7

<211> 27

<212> PRT

<213> Homo sapiens

<400> 7

Ala Gly Pro Gln Arg Ala Met Arg Val Leu Ala Met Val Val Ala Val
 1 5 10 15

Tyr Thr Ile Cys Phe Leu Pro Ser Ile Ile Phe
 20 25

<210> 8

<211> 423

<212> PRT

<213> Homo sapiens

<400> 8

Met Leu Cys His Arg Gly Gly Gln Leu Ile Val Pro Ile Ile Pro Leu
 1 5 10 15

Cys Pro Glu His Ser Cys Arg Gly Arg Arg Leu Gln Asn Leu Leu Ser
 20 25 30

Gly Pro Trp Pro Lys Gln Pro Met Glu Leu His Asn Leu Ser Ser Pro
 35 40 45

Ser Pro Ser Leu Ser Ser Ser Val Leu Pro Pro Ser Phe Ser Pro Ser
 50 55 60

Pro Ser Ser Ala Pro Ser Ala Phe Thr Thr Val Gly Gly Ser Ser Gly
 65 70 75 80

Gly Pro Cys His Pro Thr Ser Ser Ser Leu Val Ser Ala Phe Leu Ala
 85 90 95

Pro Ile Leu Ala Leu Glu Phe Val Leu Gly Leu Val Gly Asn Ser Leu
 100 105 110

Ala Leu Phe Ile Phe Cys Ile His Thr Arg Pro Trp Thr Ser Asn Thr
 115 120 125

Val Phe Leu Val Ser Leu Val Ala Ala Asp Phe Leu Leu Ile Ser Asn
 130 135 140

Leu Pro Leu Arg Val Asp Tyr Tyr Leu Leu His Glu Thr Trp Arg Phe
 145 150 155 160

Gly Ala Ala Ala Cys Lys Val Asn Leu Phe Met Leu Ser Thr Asn Arg
 165 170 175

Thr Ala Ser Val Val Phe Leu Thr Ala Ile Ala Leu Asn Arg Tyr Leu

180										185					190						
Lys	Val	Val	Gln	Pro	His	His	Val	Leu	Ser	Arg	Ala	Ser	Val	Gly	Ala						
		195						200					205								
Ala	Ala	Arg	Val	Ala	Gly	Gly	Leu	Trp	Val	Gly	Ile	Leu	Leu	Leu	Asn						
	210					215					220										
Gly	His	Leu	Leu	Leu	Ser	Thr	Phe	Ser	Gly	Pro	Ser	Cys	Leu	Ser	Tyr						
225					230					235					240						
Arg	Val	Gly	Thr	Lys	Pro	Ser	Ala	Ser	Leu	Arg	Trp	His	Gln	Ala	Leu						
				245					250					255							
Tyr	Leu	Leu	Glu	Phe	Phe	Leu	Pro	Leu	Ala	Leu	Ile	Leu	Phe	Ala	Ile						
			260					265					270								
Val	Ser	Ile	Gly	Leu	Thr	Ile	Arg	Asn	Arg	Gly	Leu	Gly	Gly	Gln	Ala						
		275					280					285									
Gly	Pro	Gln	Arg	Ala	Met	Arg	Val	Leu	Ala	Met	Val	Val	Ala	Val	Tyr						
	290					295					300										
Thr	Ile	Cys	Phe	Leu	Pro	Ser	Ile	Ile	Phe	Gly	Met	Ala	Ser	Met	Val						
305					310					315					320						
Ala	Phe	Trp	Leu	Ser	Ala	Cys	Arg	Ser	Leu	Asp	Leu	Cys	Thr	Gln	Leu						
				325					330					335							
Phe	His	Gly	Ser	Leu	Ala	Phe	Thr	Tyr	Leu	Asn	Ser	Val	Leu	Asp	Pro						
			340					345					350								
Val	Leu	Tyr	Cys	Phe	Ser	Ser	Pro	Asn	Phe	Leu	His	Gln	Ser	Arg	Ala						
		355					360					365									
Leu	Leu	Gly	Leu	Thr	Arg	Gly	Arg	Gln	Gly	Pro	Val	Ser	Asp	Glu	Ser						
		370				375					380										
Ser	Tyr	Gln	Pro	Ser	Arg	Gln	Trp	Arg	Tyr	Arg	Glu	Ala	Ser	Arg	Lys						
385					390					395					400						
Ala	Glu	Ala	Ile	Gly	Lys	Leu	Lys	Val	Gln	Gly	Glu	Val	Ser	Leu	Glu						
				405					410					415							
Lys	Glu	Gly	Ser	Ser	Gln	Gly															
			420																		

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number
WO 01/94385 A3

(51) International Patent Classification⁷: **C12N 15/12**,
C07K 14/705, C12Q 1/68, G01N 33/50, C12N 15/62,
C07K 16/28

(21) International Application Number: **PCT/EP01/06380**

(22) International Filing Date: **5 June 2001 (05.06.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/208,912 **5 June 2000 (05.06.2000) US**

(71) Applicant (for all designated States except US): **BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).**

(72) Inventor; and

(75) Inventor/Applicant (for US only): **RAMAKRISHNAN, Shyam [IN/US]; 76 Euston Road Apt. #10, Brighton, MA 02135 (US).**

(74) Common Representative: **BAYER AKTIENGESELLSCHAFT; 51368 Leverkusen (DE).**

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**

(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
10 May 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **HUMAN HM74-LIKE G PROTEIN COUPLED RECEPTOR**

(57) Abstract: Reagents which regulate human HM74-like G protein coupled receptor can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, CNS diseases such as Parkinson's disease, cardiovascular diseases such as acute heart failure, hypotension, hypertension, angina pectoris, and myocardial infarction, urinary retention, osteoporosis, obesity, ulcers, asthma, inflammation, allergies, multiple sclerosis, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, several mental retardation, and dyskinesias, such as Huntington's disease and Tourett's syndrome.

WO 01/94385 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/06380

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 C12Q1/68 G01N33/50 C12N15/62
C07K16/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 892 051 A (SMITHKLINE BEECHAM CORP) 20 January 1999 (1999-01-20) the whole document	1-13, 15-54, 57,59, 60,62, 64,66-75
X	WO 00 28032 A (INCYTE PHARMA INC ;AZIMZAI YALDA (US); CORLEY NEIL C (US); YUE HEN) 18 May 2000 (2000-05-18) see seq.ID.6 -/--	1-13, 15-54, 57,59, 60,62, 64,66-75

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

~~"E" earlier document but published on or after the international filing date~~

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"G" document member of the same patent family

Date of the actual completion of the international search

13 February 2002

Date of mailing of the international search report

26.02.2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/06380

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WO 01 31014 A (UPJOHN CO ;VOGELI GABRIEL (US); WOOD LINDA S (US); MERCHANT KALPAN) 3 May 2001 (2001-05-03)</p> <p>see CON103 (seq.ID's 5 and 6) and passages relating thereto.</p> <p>---</p>	<p>1-13, 15-26, 28-54, 57,59, 60,62, 64,66-75</p>
P,X	<p>WO 01 36471 A (ARENA PHARMACEUTICALS INC ;CHEN RUOPING (US); DANG HUONG T (US); L) 25 May 2001 (2001-05-25)</p> <p>see seq.ID.7 and 8 (hRUP11) and passages relating thereto.</p> <p>---</p>	<p>1-13, 15-32, 36-54, 69-71, 73-75</p>
P,X	<p>WO 00 71584 A (HUMAN GENOME SCIENCES INC ;LI YI (US); NI JIAN (US); FAN PING (US)) 30 November 2000 (2000-11-30)</p> <p>see clone HEOAD54 (Seq.ID's 2, 3 and 10) and passages relating thereto.</p> <p>---</p>	<p>1-13, 15-18, 21,23, 25-28, 30-54, 57,62, 64,68, 69,71-75</p>
E	<p>WO 01 57182 A (HUMAN GENOME SCIENCES INC ;ROSEN CRAIG A (US); BARASH STEVEN C (US)) 9 August 2001 (2001-08-09)</p> <p>see seq.ID's 8101 and 38817</p> <p>-----</p>	<p>1-5, 18-26, 28,29</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/06380

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0892051	A	20-01-1999	US 5955308 A	21-09-1999
			EP 0892051 A2	20-01-1999
			JP 11098988 A	13-04-1999

WO 0028032	A	18-05-2000	AU 1618500 A	29-05-2000
			EP 1129189 A2	05-09-2001
			WO 0028032 A2	18-05-2000

WO 0131014	A	03-05-2001	AU 1575601 A	08-05-2001
			WO 0131014 A2	03-05-2001

WO 0136471	A	25-05-2001	AU 1769601 A	30-05-2001
			WO 0136471 A2	25-05-2001

WO 0071584	A	30-11-2000	AU 5143700 A	12-12-2000
			WO 0071584 A1	30-11-2000

WO 0157182	A	09-08-2001	AU 2950801 A	07-08-2001
			AU 3095801 A	07-08-2001
			AU 3645901 A	07-08-2001
			AU 3646001 A	07-08-2001
			AU 3646101 A	07-08-2001
			AU 3646201 A	07-08-2001
			AU 3646301 A	07-08-2001
			AU 3646401 A	07-08-2001
			AU 3646501 A	07-08-2001
			AU 3646601 A	07-08-2001
			AU 3794301 A	07-08-2001
			AU 3794401 A	07-08-2001
			AU 3794701 A	07-08-2001
			AU 3794901 A	07-08-2001
			AU 3795001 A	07-08-2001
			AU 3795101 A	07-08-2001
			AU 3795201 A	07-08-2001
			AU 3795301 A	07-08-2001
			AU 3795401 A	07-08-2001
			AU 3795501 A	07-08-2001
			AU 3795701 A	07-08-2001
			AU 3795801 A	07-08-2001
			AU 3972601 A	07-08-2001
			AU 3972701 A	07-08-2001
			AU 3972801 A	07-08-2001
			AU 4140201 A	07-08-2001
			AU 4140301 A	07-08-2001
			AU 4140401 A	07-08-2001
			AU 4140501 A	07-08-2001
			AU 4140601 A	07-08-2001
			AU 4140701 A	07-08-2001
			AU 4140801 A	07-08-2001
			AU 4140901 A	07-08-2001
			AU 4141001 A	07-08-2001
			AU 4141101 A	20-08-2001
			AU 4141201 A	07-08-2001
			AU 4141301 A	07-08-2001
			AU 4141401 A	07-08-2001
			AU 4141501 A	07-08-2001
			AU 4141601 A	07-08-2001
			AU 4141701 A	07-08-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/06380

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0157182	A	AU 4141801 A	07-08-2001
		AU 4141901 A	07-08-2001
		AU 4313401 A	07-08-2001
		AU 4313501 A	07-08-2001
		AU 4313601 A	07-08-2001
		AU 4313701 A	14-08-2001
		AU 4526201 A	07-08-2001
		AU 4719001 A	07-08-2001
		AU 4719101 A	07-08-2001
